Nevada
|
|
2834
|
|
33-0901534
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Primary Standard Industrial
Classification Code Number)
|
|
( I.R.S. Employer Identification Number )
|
Kevin
K. Leung, Esq.
Ryan
S. Hong, Esq.
Francis
Y.L. Chen, Esq.
RICHARDSON
& PATEL LLP
10900
Wilshire Boulevard, Suite 500
Los
Angeles, California 90024
(310)
208-1182
|
Harvey
J. Kesner, Esq.
Brian
C. Daughney, Esq.
HAYNES
AND BOONE, LLP
1221
Avenue of the Americas
New
York, New York 10020
(212)
659-7300
|
Large
accelerated filer o
|
|
Accelerated
filer o
|
Non-accelerated
filer o
(Do
not check if a smaller reporting company)
|
|
Smaller
reporting company x
|
Title of Each Class of
Securities To Be Registered
|
Amount To Be
Registered
|
Proposed
Maximum
Aggregate
Offering
Price (1)
|
Amount of
Registration
Fee
|
|||||||
Share of Common Stock, $.001
par value (2)
|
2,875,000
|
$
|
20,125,000
|
$
|
790.92
|
|||||
|
||||||||||
Representative’s
Common Stock Purchase Option (3) (4)
|
1
Option
|
$
|
100
|
$
|
—
|
|||||
|
||||||||||
Shares
of Common Stock underlying Representative’s Common Stock Purchase
Option
|
125,000
|
$
|
875,000
|
34.39
|
||||||
|
||||||||||
Total
Registration Fee
|
$
|
825.31
|
(1)
|
Estimated
solely for the purpose of calculating the registration fee pursuant
to
Rule 457(o) under the Securities
Act.
|
(2)
|
Includes
375,000 shares of common stock which may be issued pursuant to
the
exercise of a 45-day option granted by the registrant to the underwriters
to cover over-allotments, if
any.
|
(3)
|
No
registration fee required pursuant to Rule 457(g) under the Securities
Act
of 1933.
|
(4)
|
Pursuant
to Rule 416 under the Securities Act of 1933, this registration statement
shall be deemed to cover the additional securities (i) to be offered
or
issued in connection with any provision of any securities purported
to be
registered hereby to be offered pursuant to terms which provide for
a
change in the amount of securities being offered or issued to prevent
dilution resulting from stock splits, stock dividends , or similar
transactions and (ii) of the same class as the securities covered
by this
registration statement issued or issuable prior to completion of
the
distribution of the securities covered by this registration statement
as a
result of a split of, or a stock dividend on, the registered securities
.
|
|
Public
offering price
|
Underwriting
discount and
commissions (1)
|
Proceeds, to
us, before
expenses (2)
|
|||||||
Per share
|
$
|
|
$
|
|
$
|
|
||||
Total
|
$
|
|
$
|
|
$
|
|
RODMAN
& RENSHAW
|
|
CANTOR
FITZGERALD & CO.
|
|
|
|
JESUP
& LAMONT SECURITIES
CORPORATION
|
(1)
|
Our
manufacturing facilities in Huxian, Xi’an, Shaanxi Province, People’s
Republic of China.
|
|
(2)
|
A
selection of our veterinary drug products for poultry and livestock
distributed in the People’s Republic of China.
|
|
(3)
|
Our
DLV chicken vaccine that is distributed in the People’s Republic of
China.
|
|
(4)
|
A
selection of our micro-organism products for poultry and livestock
distributed in the People’s Republic of
China.
|
Prospectus
Summary
|
1
|
Risk
Factors
|
9
|
Special
Note Regarding Forward Looking Statement
|
22
|
Determination
of Offering Price
|
22
|
Use
of Proceeds
|
23
|
Capitalization
|
24
|
Dilution
|
24
|
Management
|
26
|
Executive
Compensation
|
31
|
Security
Ownership of Certain Beneficial Owners and Management
|
34
|
Description
of Business
|
35
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
45
|
Certain
Relationships and Related Transactions
|
60
|
Market
For Common Equity and Related Stockholder Matters
|
62
|
Dividend
Policy
|
62
|
Description
of Securities
|
62
|
Underwriting
and Plan of Distribution
|
69
|
Legal
Matters
|
74
|
Experts
|
74
|
Disclosure
of Commission Position of Indemnification for Securities Act
Liabilities
|
74
|
Changes
in and Disagreements with Accountants on Accounting and Financial
Disclosure
|
75
|
Where
You Can Find More Information
|
75
|
Index
to Financial Statements
|
76
|
·
|
Our
vaccine line currently includes 10
products;
|
·
|
Our
veterinary medicine line for poultry and livestock currently includes
140
products;
|
·
|
Our
fodder and feed additives line currently includes 10 products;
and
|
·
|
Our
micro-organism products line currently includes 13
products.
|
·
|
publishing
advertisements and articles in national as well as specialized and
provincial newspapers, magazines, and in other media, including the
Internet;
|
·
|
participating
in national meetings, seminars, symposiums, exhibitions for veterinary
healthcare and medical care products and other related
industries;
|
·
|
organizing
cooperative promotional activities with distributors;
and
|
·
|
sending
direct mail to major farms.
|
·
|
New
bio-pharmaceutical products for animal immunization.
|
|
·
|
Protein
technology and enzyme mechanism.
|
|
·
|
Development
of non-pathogenic micro-organisms to cure gastrointestinal tract
diseases.
|
|
·
|
Veterinary
medicines for pets.
|
(1)
|
The
management of Skystar includes: Mr. Weibing Lu as Chairman and Chief
Executive Officer, Mr. Bennet P. Tchaikovsky as Chief Financial Officer,
and Mr. Wei Wen, Mr. R. Scott Cramer, Mr. Winston Yen, Mr. Qiang
Fan, Dr.
Shouguo Zhao and Dr. Chengtun Qu as members of the board of directors.
As
of the date of this prospectus: Upform Group Limited, a British Virgin
Islands company of which Mr. Lu is a director of, owns approximately
25.19% of Skystar’s issued and outstanding common stock; Clever Mind
International Limited, a British Virgin Islands company of which
Mr. Wen
is director of, owns approximately 1.11%; and Mr. Cramer owns and/or
controls approximately 4.20%. Mr. Tchaikovsky, Mr. Yen, Mr. Fan,
Dr. Zhao
and Dr. Qu do not own any shares of Skystar’s common stock as of the date
of this prospectus.
|
(2)
|
The
management of Skystar Cayman is comprised of Mr. Weibing Lu and Mr.
Wei
Wen as its Directors. Skystar is the sole shareholder of Skystar
Cayman.
|
(3)
|
The
management of Fortunate Time is comprised solely of Mr. Wei Wen as
its
Director. Skystar Cayman is the sole shareholder of Fortunate
Time.
|
(4)
|
The
management of Sida includes: Mr. Wei Wen as General Manager, Mr.
Xinya
Zhang as Vice-General Manager and Director, Mr. Lun Shen as Director
and
Ms. Erna Gao as Director. Fortunate Time is the sole shareholder
of
Sida.
|
(5)
|
Sida
Biotechnology controls Xian Tianxing Bio-Pharmaceutical through
contractual arrangements designed to mimic equity ownership of Xian
Tianxing by Sida Biotechnology. These contracts include a consulting
services agreement, operating agreement, equity pledge agreement,
option
agreement, and proxy agreement. Sida Biotechnology is a wholly-foreign
owned enterprise or “WFOE.” Most foreign entities such as us control
or hold ownership of Chinese enterprises indirectly through “WFOEs”
because it eliminates the need for a Chinese partner and does not
require
large amounts of invested capital.
|
(6)
|
The
management of Xian Tianxing includes: Mr. Weibing Lu as Chairman
and Chief
Executive Officer, Mr. Wei Wen as Vice-General Manager and Director,
Mr.
Xinya Zhang as Vice-General Manager, Ms. Erna Gao as Chief Financial
Officer and Mr. Lun Shen as Chief Engineer. As of the date of this
prospectus: Mr. Lu owns approximately 41%, and Mr. Wen approximately
5%,
of the issued and outstanding stock of Xian Tianxing; Mr. Zhang,
Ms. Gao
and Mr. Shen do not own any equity interests in Xian
Tianxing.
|
(7)
|
The
management of Shanghai Siqiang includes: Mr. Wei Wen as General
Manager, Ms. Lingmei Jin as Vice-General Manager, Mr. Fuhui Shi as
Manager
of Biological Products Department, and Mr. Chenggui Qian as Manager
of
Micro-organism Department. Xian Tianxing is the sole shareholder
of
Shanghai Siqiang.
|
Common
stock offered
|
|
2,500,000
shares at a price within the range of $5.00 to $7.00 per share
(1)
|
|
|
|
Number
of shares outstanding before this offering
|
|
1,863,911
shares (1)(2)
|
|
|
|
Number
of shares outstanding after this offering
|
|
4,363,911 shares
(1)(2)
|
Use
of Proceeds
|
|
We
intend to use the net proceeds of this offering for the completion
of a
new vaccine facility; the construction of a new production facility
for
micro-organism and feed additives; acquisitions of other companies
in the
veterinary healthcare and medical care products industries; and
working
capital and general corporate purposes, including research and
development
and marketing.
|
|
|
|
OTC
Bulletin Board symbol for our
Common Stock
|
|
SKBI.OB
|
|
|
|
Proposed
Alternext listing Symbol for Our Common Stock
|
|
BPH
|
Lock
Up Agreements
|
|
All
of our officers and directors have agreed that, for a period of
6 months
from the effective date of this offering, they will be subject
to a
lock-up agreement prohibiting any sales, transfers or hedging transactions
of our securities owned by them. See “Lock-Ups” on page
70.
|
|
|
|
Risk
Factors
|
|
The
securities offered by this prospectus are speculative and involve
a high
degree of risk and investors purchasing securities should not purchase
the
securities unless they can afford the loss of their entire investment.
See
“Risk Factors” beginning on page 9.
|
|
|
|
Representative’s
Common Stock Purchase Option
|
|
In
connection with this offering, we have also agreed to sell to the
underwriter representative an option for $100 to purchase up to
5%
(125,000 shares) of the shares of common stock sold. If this option
is
exercised, each share may be purchased by the underwriters’ representative
at $_____ per share (125% of the price of the shares sold in the
offering).
|
Nine Months Ended
September
30, (unaudited)
|
Fiscal Year Ended
December 31,
|
|||||||||||||||||||||
2008
|
2007
|
2007
|
2006
|
|||||||||||||||||||
Statements of Operations Data
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||
REVENUE
|
$
|
17,215,807
|
$
|
10,190,830
|
$
|
15,056,828
|
$
|
9,796,324
|
||||||||||||||
|
||||||||||||||||||||||
COST
OF SALES
|
8,329,025
|
4,376,670
|
6,712,365
|
5,420,652
|
||||||||||||||||||
|
||||||||||||||||||||||
GROSS
PROFIT
|
8,886,782
|
5,814,160
|
8,344,463
|
4,375,672
|
||||||||||||||||||
|
||||||||||||||||||||||
OPERATING
EXPENSES
|
||||||||||||||||||||||
Research
and development
|
369,940
|
224,486
|
268,320
|
131,371
|
||||||||||||||||||
Amortization
of deferred compensation
|
643,119
|
1,202,235
|
||||||||||||||||||||
Selling
expenses
|
1,042,267
|
434,005
|
739,422
|
475,504
|
||||||||||||||||||
General
and administrative expenses
|
1,220,796
|
1,571,812
|
1,795,876
|
881,223
|
||||||||||||||||||
|
||||||||||||||||||||||
INCOME
FROM OPERATIONS
|
6,253,779
|
3,583,857
|
4,897,726
|
1,685,339
|
||||||||||||||||||
|
||||||||||||||||||||||
OTHER
EXPENSE, NET
|
1,240,963
|
2,018,499
|
5,827,530
|
15,246
|
||||||||||||||||||
|
||||||||||||||||||||||
INCOME
BEFORE TAXES
|
5,012,816
|
1,565,358
|
(929,804
|
)
|
1,670,093
|
|||||||||||||||||
|
||||||||||||||||||||||
PROVISION
FROM INCOME TAXES
|
1,056,506
|
715,845
|
1,027,172
|
494,951
|
||||||||||||||||||
|
||||||||||||||||||||||
NET
INCOME (LOSS)
|
$
|
3,956,310
|
(1)
|
|
|
$
|
849,513
|
(2)
|
|
|
$
|
(1,956,976
|
) |
(3)
|
|
$
|
1,175,142
|
|||||
|
||||||||||||||||||||||
OTHER
COMPREHENSIVE INCOME
|
||||||||||||||||||||||
Foreign
currency translation adjustment
|
1,337,825
|
495,309
|
982,582
|
298,675
|
||||||||||||||||||
|
||||||||||||||||||||||
COMPREHENSIVE
INCOME
|
$
|
5,294,135
|
$
|
1,344,822
|
$
|
(974,394
|
)
|
$
|
1,473,817
|
|||||||||||||
|
||||||||||||||||||||||
EARNINGS
PER COMMON SHARE DATA
|
||||||||||||||||||||||
Basic
|
$
|
0.22
|
$
|
0.07
|
$
|
(0.15
|
)
|
$
|
0.11
|
|||||||||||||
Diluted
|
$
|
0.22
|
$
|
0,06
|
$
|
(0.15
|
)
|
$
|
0.09
|
|||||||||||||
|
||||||||||||||||||||||
PRO
FORMA EARNINGS PER COMMON SHARE DATA
|
||||||||||||||||||||||
Basic
(4)
|
$
|
2.19
|
$
|
.83
|
$
|
(1.45
|
)
|
$
|
1.05
|
|||||||||||||
Diluted
(4)
|
$
|
2.18
|
$
|
.80
|
$
|
(1.45
|
)
|
$
|
0.94
|
|
September 30,
2008
|
December 31,
2007
|
|||||
|
(unaudited)
|
|
|||||
Balance
Sheet Data:
|
|
|
|||||
|
|
|
|||||
Cash
and Restricted Cash
|
$
|
766,342
|
$
|
846,461
|
|||
Total
Assets
|
$
|
31,069,954
|
$
|
20,451,145
|
|||
Total
Liabilities
|
$
|
6,221,853
|
$
|
2,535,921
|
|||
Total
Stockholders’ Equity
|
$
|
24,848,101
|
$
|
17,915,224
|
·
|
offer
new and innovative products to attract and retain a larger customer
base;
|
·
|
attract
additional customers and increase spending per
customer;
|
·
|
increase
awareness of our brand and continue to develop user and customer
loyalty;
|
·
|
raise
sufficient capital to sustain and expand our
business;
|
·
|
maintain
effective control of our costs and
expenses;
|
·
|
respond
to changes in our regulatory
environment;
|
·
|
respond
to competitive market conditions;
|
·
|
manage
risks associated with intellectual property
rights;
|
·
|
attract,
retain and motivate qualified personnel;
and
|
·
|
upgrade
our technology to support additional research and development of
new
products.
|
·
|
terminates
or suspends its agreement or arrangement with
us;
|
·
|
causes
delays;
|
·
|
fails
to timely develop or manufacture in adequate quantities a substance
needed
in order to conduct clinical
trials;
|
·
|
fails
to adequately perform clinical
trials;
|
·
|
determines
not to develop, manufacture or commercialize a product to which it
has
rights;
|
·
|
pursue
other technologies or develop alternative products that compete with
the
products we are developing; or
|
·
|
otherwise
fails to meet its contractual
obligations.
|
·
|
any
of our applications for patent or exclusivity will result in their
issuance;
|
·
|
we
will develop additional patentable or proprietary
products;
|
·
|
the
exclusive rights we have been issued will provide us with any competitive
advantages;
|
·
|
the
patents or exclusive rights of others will not impede our ability
to do
business; or
|
·
|
third
parties will not be able to circumvent our proprietary
rights.
|
·
|
the
commercialization of our products could be adversely
affected;
|
·
|
any
competitive advantages of the products could be diminished;
and
|
·
|
revenues
or collaborative milestones from the products could be reduced or
delayed.
|
·
|
we
only have contractual control over Xian Tianxing. We do not own it
due to
the restriction of foreign investment in Chinese businesses;
and
|
·
|
uncertainties
relating to the regulation of the bio-pharmaceutical business in
China,
including evolving licensing practices, means that permits, licenses
or
operations at our company may be subject to challenge. This may disrupt
our business, or subject us to sanctions, requirements to increase
capital
or other conditions or enforcement, or compromise enforceability
of
related contractual arrangements, or have other harmful effects on
us.
|
·
|
actual
or anticipated fluctuations in our quarterly operating
results;
|
·
|
changes
in financial estimates by securities research
analysts;
|
·
|
conditions
in veterinary healthcare and medical care and agricultural
markets;
|
·
|
changes
in the economic performance or market valuations of other veterinary
healthcare and medical care products
companies;
|
·
|
announcements
by us or our competitors of new products, acquisitions, strategic
partnerships, joint ventures or capital
commitments;
|
·
|
addition
or departure of key personnel;
|
·
|
fluctuations
of exchange rates between RMB and the U.S.
dollar;
|
·
|
intellectual
property litigation; and
|
·
|
general
economic or political conditions in
China.
|
•
|
our
history and our prospects;
|
•
|
the
industry in which we operate;
|
•
|
the
status and development prospects for our
products;
|
•
|
our
past and present operating
results;
|
•
|
the
previous experience of our executive officers;
and
|
•
|
the
general condition of the securities markets at the time of this
offering.
|
|
Application of
|
Percentage of
|
|||||
|
Net Proceeds
|
Net Proceeds
|
|||||
|
|
|
|||||
Completion
of new vaccine facility at manufacturing plant (1)
|
$
|
2,500,000
|
18.5
|
%
|
|||
Build
a new micro-organism products and feed additive production facility
(2)
|
1,500,000
|
11.1
|
%
|
||||
Potential
business acquisition (3)
|
5,500,000
|
40.8
|
%
|
||||
Marketing
(4)
|
1,000,000
|
7.4
|
%
|
||||
Research
& Development (5)
|
2,000,000
|
14.8
|
%
|
||||
Working
capital (6)
|
1,000,000
|
7.4
|
%
|
||||
Total
|
$
|
13,500,000
|
100
|
%
|
(1)
|
Approximately
$2.5 million will be used to complete a new 5,500 square meter vaccine
workshop, constructed according to Chinese national GMP standards.
Once
completed, which is expected in the second quarter of 2009, and GMP
certified, the new workshop is anticipated to have an annual capacity
to
produce up to 6 billion doses of livestock and poultry
vaccines.
|
(2)
|
We
are also planning to construct a new production facility for
micro-organism and feed additives. Under our current planning, the
cost of
constructing the new facility, with an annual production capacity
of
approximately 4,000 tons, will be approximately $1.5 million, and
we are
looking to complete construction by March
2009.
|
(3)
|
We
may enter into acquisitions of other GMP-certified veterinary and
livestock medicine-oriented businesses in our geographic area and
other
parts of China. As of the date of this prospectus, however, we have
not
entered into letter of intent with any potential acquisition
targets.
|
(4)
|
Increase
our spending in advertising, including advertisements in trade
publications and on CCTV Channel 7 (Agricultural Channel), and to
strengthen our technical service
force.
|
(5)
|
Research
and development of veterinary medicine, vaccine, enzyme, peptide
products,
and collaboration with domestic and foreign research
institutions.
|
(6)
|
Working
capital will mainly be used for veterinary medicine production and
trial
production of vaccine products at our manufacturing base in Huxian
County
in the PRC.
|
·
|
on
an actual and pro-forma basis (giving effect to the 10-to-1 reverse
stock
split); and
|
·
|
on
a pro forma as adjusted basis to give effect to the sale of 2,500,000
shares of common stock in this offering at an assumed public offering
price of $6.00 per share, which is the midpoint of our expected
offering
range, after deducting the estimated underwriting discount and
commissions
and estimated offering expenses payable by us and application of
net
proceeds.
|
Actual
|
Pro Forma
|
Pro-Forma As
Adjusted (1)
|
||||||||
Preferred stock,
$0.001 par value, 50,000,000 shares authorized, 2,000,000 series "A"
shares issued and outstanding as of September 30, 2008.
|
$
|
2,000
|
$
|
|
$
|
2,000
|
||||
Common
stock, $0.001 par value, 20,000,000 shares authorized as of September
30,
3008; 1,865,215 shares issued and outstanding as of September
30, 2008.
|
$
|
18,652
|
$
|
2,500
|
$
|
4,366
|
||||
Paid-in-capital
|
$
|
16,315,721
|
$
|
14,997,500
|
$
|
31,313,221
|
||||
Statutory
reserves
|
$
|
2,270,690
|
$
|
—
|
$
|
2,270,690
|
||||
Retained
earnings
|
$
|
3,460,611
|
$
|
—
|
$
|
3,460,611
|
||||
Accumulated
other comprehensive income
|
$
|
2,780,427
|
$
|
—
|
$
|
2,780,427
|
||||
Total
shareholder’s equity
|
$
|
24,848,101
|
$
|
15,000,000
|
$
|
39,831,314
|
||||
Total
capitalization
|
$
|
24,848,101
|
$
|
15,000,000
|
$
|
39,831,314
|
(1)
|
A
$1.00 increase (decrease) in the assumed offering price of $6.00
per share would increase (decrease) by approximately $2.50 million
each of pro forma as adjusted paid-in capital, total stockholder’s equity
and total capitalization, assuming that the number of shares offered
by
us, as set forth on the cover page of this prospectus, remains
the same
and after deducting the underwriting discounts and commissions
payable to
the underwriters and the estimated offering expenses payable by
us.
|
Public
offering price per share (1)
|
$
|
7.00
|
||
Net
tangible book value per share before the offering
|
$
|
12.81
|
||
Decrease
in net tangible book value per share to existing shareholders attributable
to new investors (after deduction of the estimated underwriting
discount
and other offering expenses to be paid by Company)
|
$
|
3.76
|
||
Pro-forma
net tangible book value per share after the offering
|
$
|
9.05
|
||
Increased
value per share to new investors (determined by taking the adjusted
net
tangible book value after the offering and deducting the amount
of cash
paid by a new investor for a share of common stock)
|
$
|
2.05
|
|
Shares
Purchased
Number
|
Percent
|
Total
Consideration
Amount (in
000’s)
|
Percent
|
Average Price
Per Share
|
|||||||||||
|
|
|
|
|
|
|||||||||||
Existing Shareholders
|
1,865,200
|
47
|
%
|
$
|
10,427
|
41
|
%
|
$
|
5.59
|
|||||||
New
Investors
|
2,142,858
|
53
|
%
|
$
|
15,000
|
59
|
%
|
$
|
7.00
|
|||||||
Total
|
4,008,057
|
100
|
%
|
$
|
25,427
|
100
|
%
|
Name
|
|
Age
|
|
Position
|
|
Date of Appointment
|
|
|
|
|
|
|
|
Weibing
Lu
|
|
45
|
|
Chief
Executive Officer and Chairman of the Board of Directors
|
|
February
2006
|
|
|
|
|
|
|
|
Bennet
P. Tchaikovsky
|
|
39
|
|
Chief
Financial Officer
|
|
May
2008
|
|
|
|
|
|
|
|
Wei
Wen
|
|
42
|
|
Secretary
and Director
|
|
February
2006
|
|
|
|
|
|
|
|
R.
Scott Cramer
|
|
44
|
|
Director
|
|
October
2001
|
|
|
|
|
|
|
|
Qiang
Fan
|
|
53
|
|
Director
|
|
July
2008
|
|
|
|
|
|
|
|
Chengtun
Qu
|
|
44
|
|
Director
|
|
July
2008
|
|
|
|
|
|
|
|
Winston
Yen
|
|
39
|
|
Director
|
|
July 2008
|
|
|
|
|
|
|
|
Shouguo
Zhao
|
|
45
|
|
Director
|
|
July
2008
|
•
|
meeting
with our management periodically to consider the adequacy of our
internal
control over financial reporting and the objectivity of our financial
reporting;
|
|
•
|
appointing
the independent registered public accounting firm, determining the
compensation of the independent registered public accounting firm
and
pre-approving the engagement of the independent registered public
accounting firm for audit and non-audit services;
|
|
•
|
overseeing
the independent registered public accounting firm, including reviewing
independence and quality control procedures and experience and
qualifications of audit personnel that are providing us audit
services;
|
|
•
|
meeting
with the independent registered public accounting firm and reviewing
the
scope and significant findings of the audits performed by them, and
meeting with management and internal financial personnel regarding
these
matters; and
|
|
•
|
reviewing
our financing plans, the adequacy and sufficiency of our financial
and
accounting controls, practices and procedures, the activities and
recommendations of the auditors and our reporting policies and practices,
and reporting recommendations to our full board of directors for
approval.
|
SUMMARY
COMPENSATION TABLE
|
||||||||||||||||||||||||||||
Name
and
Principal Position
|
Year
|
Salary
($)
|
Bonus
($)
|
Stock
Awards
( $)
|
Option
Awards
($)
|
Non-Equity
Incentive Plan
Compensation
($)
|
|
Nonqualified
Deferred
Compensation
Earnings
($)
|
|
All Other
Compensation
( $)
|
|
Total
($)
|
||||||||||||||||
Weibing
Lu,
current
CEO
|
2007
2006
|
8,400
7,091
|
-0-
-0-
|
-0-
-0-
|
-0-
-0-
|
-0-
-0-
|
-0-
-0-
|
-0-
-0-
|
8,400
7,091
|
(1)
|
All
compensation is paid in Chinese RMB. For reporting purposes, the
amounts
in the table above have been converted to U.S. dollars at the conversion
rate of 7.6 RMB to one U.S. dollar. The officers listed in this table
received no other form of compensation in the years shown, other
than the
salary set forth in this table.
|
DIRECTOR
COMPENSATION TABLE
|
|||||||||||||||||||||||||
Name
|
|
Year
|
|
Fees
Earned
or
Paid in
Cash
($)
|
Stock
Awards
($)
|
Option
Awards
($)
|
Non-Equity
Incentive Plan
Compensation
($)
|
|
Nonqualified
Deferred
Compensation
Earnings
($)
|
All Other
Compensation
($)
|
|
Total
($)
|
|||||||||||||
Weibing
Lu (1)
|
2007
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
|||||||||||||||||
Erna
Gao (1)(2)
|
2007
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
|||||||||||||||||
Wei
Wen (1)
|
2007
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
|||||||||||||||||
Xinya
Zhang (1)(2)
|
2007
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
|||||||||||||||||
R.
Scott Cramer (3)
|
2007
|
-0-
|
-0-
|
-0-
|
-0-
|
-0-
|
64,000
|
64,000
|
(1)
|
In
connection with the share exchange transaction (described in the
Description of Business below under the heading "Corporate Organization
and History"), these persons became our directors on November 7,
2005.
After the change in control that occurred as a result of the share
exchange transaction, we do not have any compensation arrangements
with these directors.
|
(2)
|
Ms.
Erna Gao and Mr. Xinya Zhang resigned from our board of directors
effective July 14, 2008.
|
(3)
|
Mr.
Cramer was an officer of the Company prior to the share exchange
transaction and has stayed on as a director thereafter. The compensation
received by Mr. Cramer during fiscal 2007 was for services unrelated
to
his duties as a director. The compensation was paid in the form of
40,000
shares of the Company’s restricted common stock, issued on August 1, 2007
and which were not issued pursuant to any equity incentive plans
in
effect. The fair market value of our common stock on August 1, 2007
was
$1.60 per share.
|
|
Name and Address
of Beneficial Owners (1)
|
Amount
of Beneficial
Ownership (2)
|
|
Percent
of
Class (2)
|
||||||
|
|
|
|
|||||||
Common Stock
|
Upform
Group Limited (3)
|
|
469,563
|
25.19
|
%
|
|||||
Common
Stock
|
Weibing
Lu, Director and Chief Executive Officer (3)
|
|
469,563
|
25.19
|
%
|
|||||
Common
Stock
|
Wei
Wen, Director (4)
|
|
20,772
|
1.11
|
%
|
|||||
Common
Stock
|
Bennet
P. Tchaikovsky, Chief Financial Officer (5)
|
|
-0-
|
0
|
%
|
|||||
Common
Stock
|
R.
Scott Cramer, Director (6)
|
|
78,224
|
4.20
|
%
|
|||||
Common
Stock
|
Qiang
Fan, Director (7)
|
|
-0-
|
0
|
%
|
|||||
Common
Stock
|
Chengtun
Qu, Director (8)
|
|
-0-
|
0
|
%
|
|||||
Common
Stock
|
Winston
Yen, Director (9)
|
|
-0-
|
0
|
%
|
|||||
Common
Stock
|
Shouguo
Zhao, Director (10)
|
|
-0-
|
0
|
%
|
|||||
Common
Stock
|
Renaissance
US Growth Investment Trust PLC (11) (13)
|
|
291,686
|
15.65
|
%
|
|||||
Common
Stock
|
Premier
RENN US Emerging Growth Fund Ltd. (12) (13)
|
|
105,105
|
5.64
|
%
|
|||||
Common
Stock
|
All
officers and directors as a group (8 total)
|
|
568,559
|
30.50
|
%
|
(1)
|
Unless
otherwise noted, the address for each of the named beneficial owners
is:
Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District,
Xi’an,
Shaanxi Province, China.
|
(2)
|
Unless
otherwise noted, the number and percentage of outstanding shares
of common
stock of Skystar is based upon 1,863,911 shares outstanding as
of November
25, 2008, giving effect to a 10-for-1 reverse stock split to be
effected
immediately prior to the effectiveness of the registration statement
of
which this prospectus is a
part.
|
(3)
|
Upform
Group Limited’s (“Upform Group”) address is Sea Meadow House, Blackburne
Highway, P.O. Box 116, Road Town, Tortola, British Virgin Islands.
Weibing
Lu and Xinya Zhang are directors of the Upform Group. Mr. Lu is the
majority stockholder and the Chairman of the Board of Directors of
Upform
Group, and thus Mr. Lu indirectly owns the shares held by Upform
Group,
through his majority ownership of Upform Group. Thus, the number
of shares
reported herein as beneficially owned by Mr. Lu therefore includes
the
shares held by Upform Group. Similarly, because Xinya Zhang is a
director
of Upform Group, he might be deemed to have or share investment control
over Upform Group’s portfolio. Thus, the number of shares reported herein
as beneficially owned by Mr. Zhang also include the shares held by
Upform
Group.
|
(4)
|
The
number of shares reported herein as beneficially owned by Mr. Wen
includes
the shares held Clever Mind International Limited, which address
is: Sea
Meadow House, Blackburne Highway, P.O. Box 116, Road Town, Tortola,
British Virgin Islands. Mr. Wen is Chairman of the Board of Directors
of
Clever Mind and owns approximately 2.3% of the issued and outstanding
shares of Clever Mind. Because Mr. Wen is a director of Clever Mind,
he
might be deemed to have or share investment control over Clever Mind’s
portfolio.
|
(5)
|
Bennet
P. Tchaikovsky’s address is: 6571 Morningside Drive, Huntington Beach, CA
92648.
|
(6)
|
R.
Scott Cramer’s address is: 1012 Lewis Dr., Winter Park, FL 32789. Includes
771,411 shares held by the Cramer Family Trust of which Mr. Cramer
is the
sole trustee and sole primary
beneficiary.
|
(7)
|
Qiang
Fan’s address is: 9176 West Laguna Way, Elk Grove, CA
95758.
|
(8)
|
Chengtun
Qu’s address is: No. 18 Dian Zi 2nd Road, School of Chemistry &
Chemical Engineering, Xi'an Shiyou University, Xi'an,
China
|
(9)
|
Winston
Yen’s address is: 345 S. Figueroa Street, Suite 100, Los Angeles,
California 90071.
|
(10)
|
Shouguo
Zhao’s address is: No. 229 North Tai Bai Road, School of Economics and
Management, Northwest University, Xi'an,
China
|
(11)
|
Renaissance
US Growth Investment Trust PLC’s ("Renaissance") address is: 8080 North
Central Expressway, Suite 210, Dallas, Texas 75206. Russell Cleveland
is
the natural person who has voting power and the power to sell, transfer
or
otherwise dispose of the common
stock.
|
(12)
|
Premier
RENN US Emerging Growth Fund Ltd.’s (“RENN”) address is: 8080 North
Central Expressway, Suite 210, Dallas, Texas 75206. Russell Cleveland
is
the natural person who has voting power and the power to sell, transfer
or
otherwise dispose of the common
stock.
|
(13)
|
Because Renaissance
and RENN share common control, they are deemed affiliates of each
other.
|
1.
|
Our
vaccine line currently includes 10
products;
|
2.
|
Our
veterinary medicine line for poultry and livestock currently
includes 140 products;
|
3.
|
Our
fodder and feed additives line currently includes 10 products;
and
|
4.
|
Our
microorganism products line currently includes 13
products.
|
1.
|
publishing
advertisements and articles in national as well as specialized and
provincial newspapers, magazines, and in other media, including the
Internet;
|
2.
|
participating
in national meetings, seminars, symposiums, exhibitions for veterinary
healthcare and medical care products and other related
industries;
|
3.
|
organizing
cooperative promotional activities with distributors;
and
|
4.
|
sending
direct mail to major farms.
|
Veterinary
Drug Products
|
|
Approval
Number
|
Metamizole
Sodium Injection
|
|
Veterinary
Drug (2007) 270261152
|
Antondine
Injection
|
|
Veterinary
Drug (2007) 270261160
|
Dexamethasone
Sodium Phosphate Injection
|
|
Veterinary
Drug (2007) 270262530
|
Enrofloxacin
Injection
|
|
Veterinary
Drug (2007) 270262518
|
Compoumd
Vitamin B Injection
|
|
Veterinary
Drug (2007) 270264572
|
Sulfamonomethoxine
Sodium Injection
|
|
Veterinary
Drug (2007) 270261616
|
Sulfadiazine
Sodium Injection
|
|
Veterinary
Drug (2007)270261634
|
Kanamycin
Sulfate Injection
|
|
Veterinary
Drug (2007) 270261211
|
Gentamycin
Sulfate Injection
|
|
Veterinary
Drug (2007) 270261507
|
Gentamycin
Micronomicin Sulfate Injection (10 ml:100,000 parts)
|
|
Veterinary
Drug (2007) 270262751
|
Gentamycin
Micronomicin Sulfate Injection (10ml: 200,000 parts)
|
|
Veterinary
Drug (2007) 270262752
|
Mequindox
Injection (10ml:0.5g)
|
|
Veterinary
Drug (2007) 270261174
|
Mequindox
Injection (10ml:0.2g)
|
|
Veterinary
Drug (2007) 270264644
|
Vitamin
C Injection
|
|
Veterinary
Drug (2007) 270262795
|
Vitamin
B 1
Injection
|
|
Veterinary
Drug (2007) 270261389
|
Lincomycin
Hydrochloride Injection (10ml:0.3g)
|
|
Veterinary
Drug (2007) 270262614
|
Lincomycin
Hydrochloride Injection (10ml:1.5g)
|
|
Veterinary
Drug (2007) 270262616
|
Danofloxacin
Mesylate Powder
|
|
Veterinary
Drug (2008) 270262036
|
Ofloxacin
Injection
|
|
Veterinary
Drug (2007) 270262126
|
Norfloxacin
Nicotinate Injection
|
|
Veterinary
Drug (2007) 270262593
|
Ciprofloxacin
Hydrochloride Injection
|
|
Veterinary
Drug (2007) 270262160
|
Pefloxacin
Mesylate Granules
|
|
Veterinary
Drug (2007) 270262042
|
Praziquantel
Tablets
|
|
Veterinary
Drug (2007) 270261174
|
Compound
Sulfamethoxazole Tablets
|
|
Veterinary
Drug (2007) 270261612
|
Ofloxacin
Tablets
|
|
Veterinary
Drug (2007) 270262123
|
Amoxicillin
Soluble Powder
|
|
Veterinary
Drug (2007) 270261199
|
Avermectin
Powder
|
|
Veterinary
Drug (2007) 270262066
|
Diclazuril
Premix (0.2%)
|
|
Veterinary
Drug (2007) 270261140
|
Diclazuril
Premix (5%)
|
|
Veterinary
Drug (2007) 270262528
|
Florfenicol
Powder
|
|
Veterinary
Drug (2007) 270262110
|
Compound
Amoxicillin Powder
|
|
Veterinary
Drug (2007) 270262092
|
Thiamphenicol
Powder
|
|
Veterinary
Drug (2007) 270262722
|
Erythromycin
Thiocyanate Soluble Powder
|
|
Veterinary
Drug (2007) 270261492
|
Apramycin
Sulfate Soluble Powder
|
|
Veterinary
Drug (2007) 270262745
|
Neomycin
Sulfate Soluble Powder
|
|
Veterinary
Drug (2007) 270262755
|
Colistin
Sulfate Soluble Powder
|
|
Veterinary
Drug (2007)270262758
|
Salinomycin
Sodium Premix
|
|
Veterinary
Drug (2007) 270261379
|
Ciprofloxacin
Hydrochloride Soluble Powder
|
|
Veterinary
Drug (2007) 270262159
|
Spectinomycin Hydrochloride and Lincomycin Hydrochloride Soluble Powder
|
|
Veterinary Drug (2007) 270265035
|
Ofloxacin
Soluble Powder
|
|
Veterinary
Drug (2007) 270262124
|
Baitouweng
San
|
|
Veterinary
Drug (2007) 270265053
|
Baotai
Wuyou San
|
|
Veterinary
Drug (2007) 270265111
|
Chulijing
|
|
Veterinary
Drug (2007) 270265192
|
Danjibao
|
|
Veterinary
Drug (2007) 270265171
|
Feizhucai
|
|
Veterinary
Drug (2007) 270265100
|
Fuzheng
Jiedu San
|
|
Veterinary
Drug (2007) 270265076
|
Gongying
San
|
|
Veterinary
Drug (2007) 270265028
|
Houyanjing
San
|
|
Veterinary
Drug (2007) 270265179
|
Huanglian
Jiedu San
|
|
Veterinary
Drug (2007) 270265178
|
Jianji
San
|
|
Veterinary
Drug (2007) 270265133
|
Jianwei
San
|
|
Veterinary
Drug (2007) 270265134
|
Jingfang
Baidu San
|
|
Veterinary
Drug (2007) 270265127
|
Mubin
Xiaohuang San
|
|
Veterinary
Drug (2007) 270265035
|
Qingfei
Zhike San
|
|
Veterinary
Drug (2007) 270265157
|
Qingshu
San
|
|
Veterinary
Drug (2007) 270265162
|
Qingwen
Baidu San
|
|
Veterinary
Drug (2007) 270265165
|
Quchong
San
|
|
Veterinary
Drug (2007) 270265089
|
Tongru
San
|
|
Veterinary
Drug (2007) 270265156
|
Xiaoji
San
|
|
Veterinary
Drug (2007) 270265146
|
Yimu
Shenghua San
|
|
Veterinary
Drug (2007) 270265148
|
Yujin
San
|
|
Veterinary
Drug (2007) 270265102
|
Zhili
San
|
|
Veterinary
Drug (2007) 270265037
|
Compound
Sulfamethoxydiazine Sodium Injection
|
|
Veterinary
Drug (2007) 270261608
|
Lomefloxacin
Hydrochloride Soluble Powder
|
|
Veterinary
Drug (2008) 270262166
|
Danofloxacin
Mesylate Injection
|
|
Veterinary
Drug (2008) 270262033
|
Sulfathiazole
Sodium Injection
|
|
Veterinary
Drug (2008) 270261645
|
Buzhong
Yiqi San
|
|
Veterinary
Drug (2008) 270265082
|
Fangji
San
|
|
Veterinary
Drug (2008) 270265072
|
Shenling
Baishu San
|
|
Veterinary
Drug (2008) 270265093
|
Qibu
San
|
|
Veterinary
Drug (2008) 270265220
|
Sulfaquinoxaline
Sodium Soluble Powder (10%)
|
|
Veterinary
Drug (2008) 270261624
|
Sulfaquinoxaline
Sodium Soluble Powder (5%)
|
|
Veterinary
Drug (2008) 270262580
|
Fenbendazole
Powder
|
|
Veterinary
Drug (2008) 270261189
|
Sulfachloropyrazin
Sodium Soluble Powder
|
|
Veterinary
Drug (2008) 270262703
|
Huoxiang
Zhengqi San
|
|
Veterinary
Drug (2008) 270265200
|
Cuiqing
San
|
|
Veterinary
Drug (2008) 270265188
|
Longdan
Xiegan San
|
|
Veterinary
Drug (2008) 270265057
|
Maxing
Shigan San
|
|
Veterinary
Drug (2008) 270265174
|
Qumai
San
|
|
Veterinary
Drug (2008) 270265067
|
Shengru
San
|
|
Veterinary
Drug (2008) 270265051
|
Xiaoshi
Pingwei San
|
|
Veterinary
Drug (2008) 270265145
|
Xiaochaihu
San
|
|
Veterinary
Drug (2008) 270265018
|
Yinqiao
San
|
|
Veterinary
Drug (2008) 270265172
|
1.
|
Development
of protein technology and enzyme mechanism .
Introducing the technology in polypeptides, we are working to develop
new
products to cure piglet diarrhea. The products are expected to stimulate
the release of growth hormones in piglets, improve their ability
to
produce antibody and excrete stomach acidity, enhance the activity
of
albumen enzyme and adjust the activity of T.B. cells, thereby improving
their all-around disease-resistance ability. We expect these new
products
will greatly reduce the use of traditional chemical drugs and lead
to more
environmentally-friendly livestock raising. These products are now
in the
interim stage of development. We are also developing complex enzyme
preparations as new feed additives and aim to use anti-inflammatory
enzyme, polyase, and cellulose to form the best combination to effectively
dissolve and cause the additive to be absorbed in the feed. Our goal
is to
drastically improve the absorption rate of the feed, thereby reducing
the
ratio of usage of feed versus meat, while concurrently reducing the
incidence of disease in livestock and poultry. We are looking to
outsource
certain aspects of these research projects to Shaanxi Jiuzhou
Biotechnology Co., Ltd., a member of Shaanxi Jiuzhou Biomedicine
Park,
although we have not entered into any definitive
agreement.
|
2.
|
Development
of non-pathogenic micro-organisms .
We
are also developing, in cooperation with the Institute,
non-pathogenic micro-organisms and, based upon current products of
microbe
preparations, lactobacillus, bacillus, bifid bacterium baceroid,
and
combined with the most appropriate oligosaccharide preparations to
produce
living bacterium which will be applied to cure gastrointestinal tract
diseases resulting from the maladjustment of flora. If successful,
micro-organism preparations can be effective cure and prevention
for
livestock disease, and can greatly reduce the use of antibiotic and
other
drugs.
|
1.
|
Development
of new products for animal immunization by employing new technologies
in
micro-organism and bacterium .
We
expect to be placing greater resources into our research and development
with the Institution of toxoid, multivalent inactivated vaccines
and attenuated live vaccine, which we believe will gradually replace
traditional chemical drugs and which will greatly impact the animal
vaccination industry.
|
2.
|
Development
of veterinary medicines for pets .
We
believe that markets for pet-related products, including vaccines
have
been experiencing growth at a rate reflective of the growth rate
for the
general economy in China. We believe that this niche market is being
overlooked by local manufacturers. To attempt to take advantage of
this
opportunity, we have over 20 products of veterinary medicines for
pets
that are in the course of
development.
|
·
|
Revenue
recognition: Our revenues are primarily sales of veterinary healthcare
and
medical care products in China. Sales are recognized when the following
four revenue criteria are met: persuasive evidence of an arrangement
exists, delivery has occurred, the selling price is fixed or determinable,
and collectibility is reasonably assured. Sales are presented net
of value
added tax (VAT) and estimated returns of product from distributors
and/or
customers. We allow our distributors and/our customers to return
product
only if our product is later determined by us to be ineffective.
Based on
our historical experience over the past three years, product returns
have
been insignificant throughout all of our product lines: Micro-Organism,
Veterinary Medications, Feed Additives and Vaccines. Therefore, we
do not
estimate deductions for sales returns. Sales returns are taken against
revenue when products are returned from a distributor and/or
customers. Sales are presented net of any discounts given to
customers. We use this recognition policy for both distributors and
end
users.
|
(a)
|
Credit
sales:
Revenue is recognized when the products have been delivered to the
customers.
|
|
(b)
|
Full
payment before delivering:
Revenue is recognized when the products have been delivered to
customers.
|
·
|
Accounts
receivable: Some of the methods that we use to perform ongoing
credit
evaluations of our customers to adjust credit limits includes:
reviewing
payment histories, making onsite visits of the customers’ operations, and
reviewing current credit information. Some of the methods that
we use
prior to extending credit to new customers include: obtaining credit
references and reviewing the operations of our new customers. In
certain
instances, we ask that a new customer make payments upon delivery
until
such new customer can build up a sales history with us prior to
extending
credit. We continuously monitor collections and payments from our
customers and maintain a provision for estimated credit losses
based upon
historical experience and any specific customer collection issues
that
have been identified. While such credit losses have historically
been
within our expectations and the provisions established, we cannot
guarantee that we will continue to experience the same credit loss
rates
that have been experienced in the past. In June 2007, we increased
our
credit terms giving our new and existing customers 90 days to pay
instead
of 60 days to pay for certain new products and existing products
we are
looking to promote. Therefore, since July 2007, the balance of
our
accounts receivable has increased as our sales have increased.
Our
accounts receivable aging was as follows for the periods
below:
|
From
Date of Invoice to Customer:
|
September
30,
2008
|
December
31,
2007
|
December
31,
2006
|
|||||||
0-30
days
|
$
|
1,578,559
|
$
|
337,866
|
$
|
66,207
|
||||
31-60
days
|
1,227,768
|
321,557
|
64,903
|
|||||||
61-90
days
|
701,582
|
264,875
|
489
|
|||||||
91-120
days
|
175,517
|
247,247
|
--
|
|||||||
121-150
days
|
--
|
184,549
|
--
|
|||||||
Total
|
$
|
3,683,426
|
1,356,094
|
131,599
|
|
On
average, we collect our receivables within 40 days. Since December
2005,
we have collected all of our accounts receivable and have had
no write
offs. This is attributed to the steps that we take prior to
extending
credit to our customers as discussed above. If we are having
difficulty
collecting from a customer, we take the following steps: cease
existing
shipments to the customer, our sales force actively calls and
goes to the
customer’s site reminding the customer of their past due invoice and
requesting payment, and if those methods are unsuccessful we
use our
outside legal counsel. If, in the future, those steps are unsuccessful,
management would determine whether or not the receivable should
be written
off.
|
·
|
Convertible
debentures and warrants: We have adopted APB No. 14, Accounting for
Convertible Debt and Debt Issued with Stock Purchase Warrants, FAS
133,
EITF-98-5, and EITF-00-27, for valuation and accounting treatment
of our
outstanding convertible debentures and
warrants.
|
·
|
Liquidated
damages: We have adopted FAS 5 and FSP EITF 00-19-2 in connection
with the
liquidated damages we accrued pursuant to the terms of our Registration
Rights Agreement with certain investors dated February 27,
2007.
|
|
Three Months Ended September 30,
|
||||||||||||
|
2008
|
|
2007
|
|
|||||||||
|
(unaudited,
in U.S. Dollars, except for percentages)
|
||||||||||||
Revenues
|
$
|
10,051,259
|
100.00
|
%
|
$
|
5,448,561
|
100.00
|
%
|
|||||
Gross
Profit
|
$
|
5,186,137
|
51.60
|
%
|
$
|
3,180,217
|
58.37
|
%
|
|||||
Operating
Expense
|
$
|
1,071,292
|
10.66
|
%
|
$
|
681,959
|
12.52
|
%
|
|||||
Income
From Operations
|
$
|
4,114,845
|
40.94
|
%
|
$
|
2,498,258
|
45.85
|
%
|
|||||
Other
Expenses
|
$
|
(6,755
|
)
|
(0.07
|
)%
|
$
|
(1,010,758
|
)
|
(18.55
|
)%
|
|||
Income
Tax Expenses
|
$
|
642,066
|
6.39
|
%
|
$
|
415,578
|
7.63
|
%
|
|||||
Net
Income
|
$
|
3,466,024
|
34.48
|
%
|
$
|
1,071,922
|
19.67
|
%
|
|
Three
Months Ended September 30,
|
||||||||||||
|
2008
|
|
2007
|
|
|||||||||
|
(unaudited,
in U.S. dollars, except for percentages)
|
|
|||||||||||
Total
Net Revenues
|
$
|
10,051,259
|
100.00
|
%
|
$
|
5,448,561
|
100.00
|
%
|
|||||
Raw
materials
|
$
|
4,689,914
|
46.65
|
%
|
$
|
2,119,515
|
38.90
|
%
|
|||||
Labor
|
$
|
42,724
|
0.
43
|
%
|
$
|
55,806
|
1.02
|
%
|
|||||
Manufacturing
Overhead
|
$
|
132,484
|
1.32
|
%
|
$
|
93,023
|
1.71
|
%
|
|||||
Total
Cost of Goods Sold
|
$
|
4,865,122
|
48.40
|
%
|
$
|
2,268,344
|
41.63
|
%
|
|||||
|
|||||||||||||
Gross
Profit
|
$
|
5,186,137
|
51.60
|
%
|
$
|
3,180,217
|
58.37
|
%
|
|
For the Three Months Ended September 30,
|
||||||||||||
|
2008
|
|
2007
|
|
|||||||||
|
|
% of Total
Net Sales
|
|
% of Total
Net Sales
|
|||||||||
|
(unaudited,
in U.S. Dollars, except for percentages)
|
||||||||||||
Gross
Profit
|
$
|
5,186,137
|
51.60
|
%
|
$
|
3,180,217
|
58.37
|
%
|
|||||
Operating
Expenses
|
$
|
1,071,292
|
10.66
|
%
|
$
|
681,959
|
12.52
|
%
|
|||||
Selling
Expenses
|
$
|
549,580
|
5.47
|
%
|
$
|
176,438
|
3.24
|
%
|
|||||
General
and Administrative Expenses
|
$
|
318,470
|
3.17
|
%
|
$
|
387,916
|
7.12
|
%
|
|||||
Research
and Development Costs
|
$
|
203,242
|
2.02
|
%
|
$
|
117,605
|
2.16
|
%
|
|||||
Income
from Operations
|
$
|
4,114,845
|
40.94
|
%
|
$
|
2,498,258
|
45.85
|
%
|
|
Nine
Months Ended September 30,
|
||||||||||||
|
2008
|
2007
|
|||||||||||
|
(unaudited,
in U.S. Dollars, except for percentages)
|
||||||||||||
Revenues
|
$
|
17,215,807
|
100.00
|
%
|
$
|
10,190,830
|
100.00
|
%
|
|||||
Gross
Profit
|
$
|
8,886,782
|
51.62
|
%
|
$
|
5,814,160
|
57.05
|
%
|
|||||
Operating
Expense
|
$
|
2,633,003
|
15.29
|
%
|
$
|
2,230,303
|
21.89
|
%
|
|||||
Income
From Operations
|
$
|
6,253,779
|
36.33
|
%
|
$
|
3,583,857
|
35.16
|
%
|
|||||
Other
Expenses
|
$
|
(1,240,963
|
)
|
(7.21
|
)%
|
$
|
(2,018,499
|
)
|
(19.80
|
)%
|
|||
Income
tax expenses
|
$
|
1,056,506
|
6.14
|
%
|
$
|
715,845
|
7.02
|
%
|
|||||
Net
Income
|
$
|
3,956,310
|
22.98
|
%
|
$
|
849,513
|
8.34
|
%
|
|
Nine
Months Ended September 30,
|
||||||||||||
|
2008
|
|
2007
|
||||||||||
|
|
(unaudited,
in U.S. dollars, except for percentages)
|
|||||||||||
Total
Net Revenues
|
|
$
|
17,215,807
|
100.00
|
%
|
$
|
10,190,830
|
100.00
|
%
|
||||
Raw
materials
|
$
|
7,863,477
|
45.68
|
%
|
$
|
4,023,907
|
39.49
|
%
|
|||||
Labor
|
$
|
136,434
|
0.79
|
%
|
$
|
171,487
|
1.68
|
%
|
|||||
Manufacturing
Overhead
|
$
|
329,114
|
1.91
|
%
|
$
|
181,276
|
1.78
|
%
|
|||||
Total
Cost of Goods Sold
|
$
|
8,329,025
|
48.38
|
%
|
$
|
4,376,670
|
42.95
|
%
|
|||||
|
|||||||||||||
Gross
Profit
|
$
|
8,886,782
|
51.62
|
%
|
$
|
5,814,160
|
57.05
|
%
|
|
For the Nine Months Ended September 30,
|
||||||||||||
|
2008
|
2007
|
|
||||||||||
|
|
|
$% of Total
Net Sales
|
|
|
$% of Total
Net Sales
|
|||||||
|
(unaudited,
in U.S. Dollars, except for percentages)
|
||||||||||||
Gross
Profit
|
$
|
8,886,782
|
51.62
|
%
|
$
|
5,814,160
|
57.05
|
%
|
|||||
Operating
Expenses:
|
$
|
2,633,003
|
15.29
|
%
|
$
|
2,230,303
|
21.88
|
%
|
|||||
Selling
Expenses
|
$
|
1,042,267
|
6.05
|
%
|
$
|
434,005
|
4.26
|
%
|
|||||
General
and Administrative Expenses
|
$
|
1,220,796
|
7.09
|
%
|
$
|
1,571,812
|
15.42
|
%
|
|||||
Research
and Development Costs
|
$
|
369,940
|
2.15
|
%
|
$
|
224,486
|
2.20
|
%
|
|||||
Income
from Operations
|
$
|
6,253,779
|
36.33
|
%
|
3,583,857
|
35.17
|
%
|
|
For the Twelve Months Ended December 31,
|
||||||||||||
|
2007
|
|
2006
|
||||||||||
|
(in U.S. Dollars, except for percentages)
|
||||||||||||
Revenues
|
$
|
15,056,828
|
100.00
|
%
|
$
|
9,796,324
|
100.00
|
%
|
|||||
Gross
Profit
|
$
|
8,344,463
|
55.42
|
%
|
$
|
4,375,672
|
44.67
|
%
|
|||||
Operating
Expense
|
$
|
3,446,737
|
22.89
|
%
|
$
|
2,690,333
|
27.46
|
%
|
|||||
Income
From Operations
|
$
|
4,897,726
|
32.53
|
%
|
$
|
1,685,339
|
17.20
|
%
|
|||||
Other
Expenses
|
$
|
5,827,530
|
38.70
|
%
|
$
|
15,246
|
0.16
|
%
|
|||||
Income
tax expenses
|
$
|
1,027,172
|
6.82
|
%
|
$
|
494,951
|
5.05
|
%
|
|||||
Net
(Loss) Income
|
$
|
(1,956,976
|
)
|
(13.00
|
)%
|
$
|
1,175,142
|
12.00
|
%
|
|
For the Twelve Months Ended December 31,
|
||||||||||||
|
2007
|
|
2006
|
||||||||||
|
(in U.S. dollars, except for percentages)
|
||||||||||||
Total
Net Revenues
|
$
|
15,056,828
|
100.00
|
%
|
$
|
9,796,324
|
100.00
|
%
|
|||||
Raw
materials
|
$
|
6,153,671
|
40.87
|
%
|
$
|
5,127,499
|
52.34
|
%
|
|||||
Labor
|
$
|
251,676
|
1.67
|
%
|
$
|
228,278
|
2.33
|
%
|
|||||
Manufacturing
Overhead
|
$
|
307,018
|
2.04
|
%
|
$
|
64,875
|
0.66
|
%
|
|||||
Total
Cost of Sales
|
$
|
6,712,365
|
44.58
|
%
|
$
|
5,420,652
|
55.33
|
%
|
|||||
|
|||||||||||||
Gross
Profit
|
$
|
8,344,463
|
55.42
|
%
|
$
|
4,375,672
|
44.67
|
%
|
|
For the Twelve Months Ended December 31,
|
||||||||||||
|
2007
|
|
2006
|
|
|||||||||
|
|
$% of Total
Net Sales
|
|
$% of Total
Net Sales
|
|
||||||||
|
(in U.S. Dollars, except for percentages)
|
||||||||||||
Gross Profit
|
$
|
8,344,463
|
55.42
|
%
|
$
|
4,375,672
|
44.67
|
%
|
|||||
Operating
Expenses:
|
|||||||||||||
Selling
Expenses
|
739,422
|
4.91
|
%
|
475,504
|
4.85
|
%
|
|||||||
General
and Administrative Expenses
|
2,438,995
|
16.20
|
%
|
2,083,458
|
21.27
|
%
|
|||||||
Research
and Development Costs
|
268,320
|
1.78
|
%
|
131,371
|
1.34
|
%
|
|||||||
Income
from Operations
|
4,897,726
|
32.53
|
%
|
1,685,339
|
17.20
|
%
|
|
Payments due by Period
|
|||||||||||||||
Contractual Obligations
|
Total
|
|
Less than
1 year
|
1-3 years
|
3-5 years
|
More than
5 years
|
||||||||||
Long-Term
Debt Obligations
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
||||||
R&D
Project Obligation
|
204,000
|
204,000
|
||||||||||||||
Operating
Lease Obligations
|
343,618
|
57,821
|
116,254
|
75,733
|
93,810
|
|||||||||||
Total
|
$
|
547,618
|
$
|
261,821
|
$
|
116,254
|
$
|
75,733
|
$
|
93,810
|
September
30, 2008
|
December
31, 2007
|
September
30, 2007
|
December
31, 2006
|
||||||||||
Assets
and liabilities
|
USD0.1463:
RMB1
|
US
$ 0.1371:
RMB1
|
USD0.1334:
RMB1
|
$
|
US0.12820:
RMB1
|
||||||||
|
|||||||||||||
Statements
of operations and cash flows for the period/year ended
|
USD0.14337:
RMB1
|
$
|
US0.13167:
RMB1
|
USD0.13064:
RMB1
|
$
|
US0.12557:
RMB1
|
1.
|
Micro-organism
plant.
This production plant is run in cooperation with experts from Japan
Kato
Microbiology Institute, Microbiology Institute of Shaanxi Province
and
Northwest Agro-Forestry Sci-tech University. This facility was
expanded in
2007 from approximately 16,100 square feet to approximately 21,
500 square
feet in accordance with Chinese national Good Manufacturing Practice
(“GMP”) standards, and has been issued production permit and certain
product approval numbers by the Chinese Ministry of
Agriculture.
|
2.
|
Feed
additive plant.
This production facility occupies an area of approximately 10,700
square
feet.
|
Description
|
|
Approximate Size
|
|
Status
|
GMP
standard veterinary medicine facility
|
|
45,200
square feet
|
|
Completed
|
|
|
|
|
|
Quality
control, research and development, and administration
building
|
|
36,600
square feet
|
|
Completed
|
|
|
|
|
|
GMP
standard bio-pharmaceutical facility with three production lines
for
active bacteria, inactivated vaccines, and coccidiosis
vaccines
|
|
48,400
square feet
|
|
Completion
expected in the second quarter of 2009
|
|
|
|
|
|
Animal
laboratory complying with Animal Bio-safety Level 2 (ABSL-2)
requirements
|
|
10,700
square feet
|
|
Completion
expected in the second quarter of
2009
|
|
September
30,
2008
|
December 31,
2007
|
|
December 31,
2006
|
|
|||||
|
|
(unaudited)
|
|
|
||||||
Amounts
due from shareholder:
|
|
|
|
|||||||
Mr.
Weibing Lu (1)
|
$
|
-
|
$
|
59,462
|
$
|
-
|
||||
|
||||||||||
Amount
due to shareholders:
|
||||||||||
Ms.
Aixia Wang (1)
|
$
|
8,788
|
$
|
1,371
|
-
|
|||||
Ms.
Aixia Wang (2)
|
43,890
|
-
|
-
|
|||||||
Mr.
Weibing Lu (2)
|
219,450
|
-
|
-
|
|||||||
Mr.
Wei Wen (2)
|
43,890
|
-
|
-
|
|||||||
Mr.
Scott Cramer (1)
|
30,245
|
30,245
|
-
|
|||||||
Total
|
$
|
386,712
|
$
|
31,616
|
$
|
-
|
||||
|
||||||||||
Amount
due to related companies:
|
||||||||||
TianXing
Digital Co., Ltd. (3)
|
$
|
-
|
$
|
17,137
|
$
|
16,025
|
||||
Shanxi
Xingji Electronics Co. Ltd. (3)
|
4,361
|
32,817
|
-
|
|||||||
Total
|
$
|
4,361
|
$
|
49,954
|
16,025
|
(1)
|
The
related individuals, Mr. Weibing Lu, Ms. Aixia Wang, and Mr. R. Scott
Cramer are all shareholders of the Company. Mr. Lu and Mr. Cramer
are also
our directors, and Mr. Lu is additionally our chief executive officer.
The
amounts due from Mr. Lu were expense advances for Mr. Lu’s
business-related travels on behalf of the Company. Mr. Lu was permitted
to
continue drawing on the expense advancement toward his travels through
the
second quarter of fiscal 2008, at the end of which Mr. Lu returned
to the
Company the then remaining unsubstantiated balance of the advance.
Going
forward, we do not intend to provide Mr. Lu or any other management
members with similar type of expense advancement until such time
that our
board of directors, comprising of a majority of independent directors,
shall have determined that such arrangement is appropriate and/or
necessary for the Company, and have adopted specific policy and procedure
accordingly. The amounts due to Ms. Wang and Mr. Cramer were cash
advances
to facilitate Company operations or expenses paid by these individuals
on
behalf of the Company. These balances are non-interest bearing, unsecured,
due on demand, and the ultimate manner of settlement is in cash or
in
exchange for office premises
rental.
|
(2)
|
The
related individuals, Weibing Lu, Aixia Wang, and Wei Wen are all
shareholders of the Company. Mr. Lu and Mr. Wen are also the directors
of
the Company, with Mr. Lu additionally being the chief executive
office.
These individuals obtained personal loans from the bank and advanced
the
proceeds to facilitate Xian Tianxing’s operations. The short-term loan
with balance of $175,080 and $43,890 from Mr. Lu bears annual interest
at
7.47% and $8.44%, respectively and due on December 30, 2008 and
May 29,
2009, respectively. The short-term loan from Ms Wang and Mr. Wen
with
balance of $43,890 each bears annual interest at 8.44% and due
on May 29,
2009, respectively.
|
(3)
|
Shanxi
Xingji Electronics Co., Ltd. is owned by the wife of Mr. Lu, and
Tianxing
Digital Co., Ltd. is owned by Mr. Lu. The amounts due to Shanxi Xingji
Electronics Co., Ltd. and Tianxing Digital Co., Ltd. are short term
cash
transfers for business operations, non-interest bearing, unsecured,
and
payable upon demand. The ultimate manner of settlement is in
cash.
|
Quarter Ended
|
High Bid
|
Low Bid
|
|||||
September
30, 2008
|
$
|
11,00
|
$
|
5.00
|
|||
June
30, 2008
|
$
|
11.50
|
$
|
10.10
|
|||
March
31, 2008
|
$
|
14.00
|
$
|
9,80
|
|||
|
|||||||
December
31, 2007
|
$
|
18.50
|
$
|
10.50
|
|||
September
30, 2007
|
$
|
18.50
|
$
|
10.50
|
|||
June
30, 2007
|
$
|
16.90
|
$
|
10,40
|
|||
March
31, 2007
|
$
|
18.40
|
$
|
13.00
|
|||
|
|||||||
December
31, 2006
|
$
|
26.00
|
$
|
12.00
|
|||
September
30, 2006
|
$
|
21.10
|
$
|
18.00
|
|||
June
30, 2006
|
$
|
27.00
|
$
|
11.00
|
|||
March
31, 2006
|
$
|
55.80
|
$
|
16.00
|
Name
|
|
Number of Shares
|
|
|
Rodman
& Renshaw, LLC
|
|
|
|
|
Cantor
Fitzgerald & Co.
|
|
|
|
|
Jesup
& Lamont Securities Corporation
|
|
|
|
|
Total
|
|
|
|
·
|
the
information in this prospectus and otherwise available to the
underwriters;
|
·
|
the
history and the prospects for the industry in which we will
compete;
|
·
|
the
valuation of our company based on, among other factors, the offering
prices of our recent private
offerings;
|
·
|
our
current financial condition and the prospects for our future cash
flows
and earnings;
|
·
|
the
general condition of the economy and the securities markets at
the time of
this offering;
|
·
|
the
recent market prices of, and the demand for, publicly-traded securities
of
generally comparable companies;
and
|
·
|
the
public demand for our securities in this
offering.
|
|
Total
|
|||||||||
Per
Share
|
|
|
Without
Over-
Allotment
|
|
With
Over-
Allotment
|
|||||
Public
offering price
|
$
|
|
$
|
|
$
|
|
||||
|
||||||||||
Underwriting
discount (1)
|
$
|
|
$
|
|
$
|
|
||||
|
||||||||||
Non-accountable
expense allowance (2)
|
$
|
|
$
|
|
$
|
|
||||
|
||||||||||
Proceeds,
before expenses, to us (3)
|
$
|
|
$
|
|
$
|
|
(1)
|
Underwriting
discount is $______ per share (7% of the price of the shares sold
in the
offering).
|
(2)
|
The
non-accountable expense allowance of 1% is not payable with respect
to the
shares sold upon exercise of the underwriters’ over-allotment
option.
|
(3)
|
We
estimate that the total expenses of this offering, excluding the
underwriters’ discount and the non-accountable expense allowance, are
approximately $______.
|
•
|
our
history and our prospects;
|
|
•
|
the
price of our common stock;
|
•
|
the
industry in which we operate;
|
|
•
|
the
status and development prospects for our
products;
|
•
|
our
past and present operating results;
|
|
•
|
the
previous experience of our executive officers;
and
|
•
|
the
general condition of the securities markets at the time of this
offering.
|
·
|
Stabilizing
transactions permit bids or purchases for the purpose of pegging,
fixing
or maintaining the price of the common stock, so long as stabilizing
bids
do not exceed a specified maximum.
|
·
|
Over-allotment
involves sales by the underwriters of shares in excess of the number
of
shares the underwriters are obligated to purchase, which creates
a short
position. The short position may be either a covered short position
or a
naked short position. In a covered short position, the number of
shares
over-allotted by the underwriters is not greater than the number
of shares
that they may purchase in the over-allotment option. In a naked short
position, the number of shares involved is greater than the number
of
shares in the over-allotment option. The underwriters may close out
any
covered short position by either exercising their over-allotment
option or
purchasing shares in the open
market.
|
·
|
Covering
transactions involve the purchase of securities in the open market
after
the distribution has been completed in order to cover short positions.
In
determining the source of securities to close out the short position,
the
underwriters will consider, among other things, the price of securities
available for purchase in the open market as compared to the price
at
which they may purchase securities through the over-allotment option.
If
the underwriters sell more shares of common stock than could be covered
by
the over-allotment option, creating a naked short position, the position
can only be closed out by buying securities in the open market. A
naked
short position is more likely to be created if the underwriters are
concerned that there could be downward pressure on the price of the
securities in the open market after pricing that could adversely
affect
investors who purchase in this
offering.
|
·
|
Penalty
bids permit the underwriters to reclaim a selling concession from
a
selected dealer when the shares of common stock originally sold by
the
selected dealer are purchased in a stabilizing or syndicate covering
transaction.
|
|
|
Page
|
|
|
|
CONSOLIDATED
BALANCE SHEETS AS OF SEPTEMBER 30, 2008 AND 2007
(UNAUDITED)
|
|
F-1
|
|
|
|
CONSOLIDATED
STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME FOR THE
THREE AND
NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007 (UNAUDITED)
|
|
F-2
|
|
|
|
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)
|
|
F-3
|
|
|
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30,
2008 AND
2007 (UNAUDITED)
|
|
F-4
|
|
|
|
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2008
(UNAUDITED)
|
|
F-5
|
|
|
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
|
F-27
|
|
|
|
CONSOLIDATED
BALANCE SHEETS AS OF DECEMBER 31, 2007 AND 2006
|
|
F-28
|
|
|
|
CONSOLIDATED
STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)
FOR THE
YEARS ENDED DECEMBER 31, 2007 and 2006
|
|
F-29
|
|
|
|
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS' EQUITY
|
|
F-30
|
|
|
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2007
AND
2006
|
|
F-31
|
|
|
|
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31,
2007
|
|
F-32
|
September 30, 2008
|
December 31, 2007
|
||||||
(Unaudited)
|
|||||||
ASSETS
|
|||||||
|
|
|
|||||
CURRENT
ASSETS:
|
|
|
|||||
Cash
|
$
|
685,826
|
$
|
771,492
|
|||
Restricted
cash
|
80,516
|
74,969
|
|||||
Accounts
receivable, net of allowance for doubtful accounts of $213,036
and
$199,639 as of September 30, 2008 and December 31, 2007,
respectively.
|
3,683,426
|
1,356,094
|
|||||
Inventories
|
5,968,988
|
2,242,611
|
|||||
Deposits
and prepaid expenses
|
4,017,692
|
806,657
|
|||||
Loans
receivable
|
434,036
|
968,852
|
|||||
Other
receivables
|
160,902
|
43,800
|
|||||
Other
receivables-related party
|
-
|
59,462
|
|||||
Total
current assets
|
15,031,386
|
6,323,937
|
|||||
|
|||||||
PLANT
AND EQUIPMENT, net
|
13,904,466
|
11,793,967
|
|||||
|
|||||||
OTHER
ASSETS:
|
|||||||
Long
term prepayment
|
1,170,400
|
1,220,190
|
|||||
Deferred
financing costs
|
-
|
101,815
|
|||||
Intangible,
net
|
963,702
|
1,011,236
|
|||||
Total
other assets
|
2,134,102
|
2,333,241
|
|||||
Total
assets
|
$
|
31,069,954
|
$
|
20,451,145
|
|||
|
|||||||
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
|||||||
|
|||||||
CURRENT
LIABILITIES:
|
|||||||
Accounts
payable
|
$
|
247,474
|
$
|
126,754
|
|||
Accrued
expenses
|
807,902
|
502,871
|
|||||
Short
term loan, interest bearing
|
731,500
|
-
|
|||||
Deposits
from customers
|
248,994
|
61,706
|
|||||
Taxes
payable
|
2,613,110
|
568,797
|
|||||
Other
payables
|
84,550
|
81,221
|
|||||
Amount
due to related companies
|
4,361
|
49,954
|
|||||
Amount
due to shareholders and directors
|
386,712
|
31,616
|
|||||
Total
current liabilities
|
5,124,603
|
1,422,919
|
|||||
|
|||||||
OTHER
LIABILITIES:
|
|||||||
Deferred
government grant
|
1,097,250
|
1,028,250
|
|||||
Convertible
debenture, net of $398,171 discount as of December 31,
2007
|
-
|
84,752
|
|||||
Total
other liabilities
|
1,097,250
|
1,113,002
|
|||||
Total
liabilities
|
6,221,853
|
2,535,921
|
|||||
|
|||||||
CONTINGENT
LIABILITIES
|
-
|
-
|
|||||
|
|||||||
SHAREHOLDERS'
EQUITY:
|
|||||||
Preferred
stock, $0.001 par value, 50,000,000 shares authorized, 2,000,000
series
"A" shares issued and outstanding as of September 30, 2008 and
December
31, 2007, respectively; Nil series "B" shares issued and outstanding
as of
September 30, 2008 and December 31,2007, respectively.
|
2,000
|
2,000
|
|||||
Common
stock, $0.001 par value, 200,000,000 shares authorized; 18,652,146
and
17,111,200 shares issued and outstanding as of September 30, 2008
and
December 31, 2007, respectively.
|
18,652
|
17,111
|
|||||
Paid-in-capital
|
16,315,721
|
14,741,278
|
|||||
Deferred
compensation
|
-
|
(62,758
|
) | ||||
Statutory
reserves
|
2,270,690
|
1,652,720
|
|||||
Retained
earnings
|
3,460,611
|
122,271
|
|||||
Accumulated
other comprehensive income
|
2,780,427
|
1,442,602
|
|||||
Total
shareholders' equity
|
24,848,101
|
17,915,224
|
|||||
Total
liabilities and shareholders' equity
|
$
|
31,069,954
|
$
|
20,451,145
|
|
Three months ended
|
Nine months ended
|
|||||||||||
|
|
September 30,
|
|
September 30,
|
|||||||||
|
2008
|
|
2007
|
2008
|
|
2007
|
|
||||||
|
|
|
|
|
|||||||||
REVENUE
|
$
|
10,051,259
|
$
|
5,448,561
|
$
|
17,215,807
|
$
|
10,190,830
|
|||||
COST
OF SALES
|
4,865,122
|
2,268,344
|
8,329,025
|
4,376,670
|
|||||||||
|
|||||||||||||
GROSS
PROFIT
|
5,186,137
|
3,180,217
|
8,886,782
|
5,814,160
|
|||||||||
|
|||||||||||||
OPERATING
EXPENSES
|
|||||||||||||
Research
and development
|
203,242
|
117,605
|
369,940
|
224,486
|
|||||||||
Selling
expenses
|
549,580
|
176,438
|
1,042,267
|
434,005
|
|||||||||
General
and administrative
|
318,470
|
387,916
|
1,220,796
|
1,571,812
|
|||||||||
Total
operating expenses
|
1,071,292
|
681,959
|
2,633,003
|
2,230,303
|
|||||||||
|
|||||||||||||
INCOME
FROM OPERATIONS
|
4,114,845
|
2,498,258
|
6,253,779
|
3,583,857
|
|||||||||
|
|||||||||||||
OTHER
INCOME (EXPENSE)
|
|||||||||||||
Other
income
|
328
|
-
|
830
|
-
|
|||||||||
Other
expense
|
(494
|
)
|
(183,119
|
)
|
(494,254
|
)
|
(324,345
|
)
|
|||||
Interest
income
|
519
|
-
|
33,103
|
130
|
|||||||||
Interest
expense
|
(7,108
|
)
|
(827,639
|
)
|
(522,867
|
)
|
(1,694,284
|
)
|
|||||
Inducement
cost for debentures converted
|
-
|
-
|
(257,775
|
)
|
-
|
||||||||
Total
other income (expense)
|
(6,755
|
)
|
(1,010,758
|
)
|
(1,240,963
|
)
|
(2,018,499
|
)
|
|||||
|
|||||||||||||
INCOME
BEFORE PROVISION FOR INCOME TAXES
|
4,108,090
|
1,487,500
|
5,012,816
|
1,565,358
|
|||||||||
|
|||||||||||||
PROVISION
FOR INCOME TAXES
|
642,066
|
415,578
|
1,056,506
|
715,845
|
|||||||||
|
|||||||||||||
NET
INCOME
|
3,466,024
|
1,071,922
|
3,956,310
|
849,513
|
|||||||||
|
|||||||||||||
OTHER
COMPREHENSIVE INCOME :
|
|||||||||||||
Foreign
currency translation adjustment
|
110,845
|
211,633
|
1,337,825
|
495,309
|
|||||||||
|
|||||||||||||
COMPREHENSIVE
INCOME
|
$
|
3,576,869
|
$
|
1,283,555
|
$
|
5,294,135
|
$
|
1,344,822
|
|||||
|
|||||||||||||
EARNINGS
PER SHARE
|
|||||||||||||
Basic
|
$
|
0.19
|
$
|
0.08
|
$
|
0.22
|
$
|
0.07
|
|||||
Diluted
|
$
|
0.19
|
$
|
0.08
|
$
|
0.22
|
$
|
0.06
|
|||||
|
|||||||||||||
WEIGHTED
AVERAGE NUMBER OF COMMON SHARES
|
|||||||||||||
Basic
|
18,647,042
|
12,865,739
|
18,085,395
|
12,819,290
|
|||||||||
Diluted
|
18,647,042
|
13,232,060
|
18,126,355
|
13,325,955
|
|
|
|
|
|
Retained earnings
|
|
Accumulated
other
|
|
|
|
|||||||||||||||||||||
|
|
Preferred stock
|
|
Common stock
|
|
Paid-in
|
|
Deferred
|
|
Statutory
|
|
|
comprehensive
|
|
|
||||||||||||||||
|
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
capital
|
Compensation
|
reserves
|
Unrestricted
|
income
|
|
Total
|
|||||||||||||||||
BALANCE,
December 31, 2006
|
2,000,000
|
$
|
2,000
|
12,795,549
|
$
|
12,795
|
$
|
6,246,325
|
$
|
(705,877
|
)
|
$
|
779,624
|
$
|
2,952,343
|
$
|
460,020
|
$
|
9,747,230
|
||||||||||||
Shares
issued for services
|
78,750
|
79
|
115,684
|
115,763
|
|||||||||||||||||||||||||||
Beneficial
conversion feature of debentures
|
2,130,575
|
2,130,575
|
|||||||||||||||||||||||||||||
Warrants
issued to debenture holders
|
1,944,425
|
1,944,425
|
|||||||||||||||||||||||||||||
Warrants
issued to placement agent
|
643,277
|
643,277
|
|||||||||||||||||||||||||||||
Amortization
of deferred compensation
|
563,619
|
563,619
|
|||||||||||||||||||||||||||||
Foreign
currency translation
|
495,309
|
495,309
|
|||||||||||||||||||||||||||||
Net
loss
|
849,513
|
849,513
|
|||||||||||||||||||||||||||||
Appropriation
to statutory reserve
|
|
|
|
|
|
|
410,961
|
(410,961
|
)
|
|
-
|
||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
BALANCE,
September 30, 2007, (Unaudited)
|
2,000,000
|
$
|
2,000
|
12,874,299
|
$
|
12,874
|
$
|
11,080,286
|
$
|
(142,258
|
)
|
$
|
1,190,585
|
$
|
3,390,895
|
$
|
955,329
|
$
|
16,489,711
|
||||||||||||
|
|||||||||||||||||||||||||||||||
Inducement
cost for debentures converted
|
634,450
|
634,450
|
|||||||||||||||||||||||||||||
Inducement
cost for warrants exercised
|
279,547
|
279,547
|
|||||||||||||||||||||||||||||
Debentures
converted to common stock
|
3,278,720
|
3,279
|
2,747,953
|
2,751,232
|
|||||||||||||||||||||||||||
Cashless
exercise of warrants
|
958,181
|
958
|
(958
|
-
|
|||||||||||||||||||||||||||
Amortization
of deferred compensation
|
79,500
|
79,500
|
|||||||||||||||||||||||||||||
Foreign
currency translation
|
487,273
|
487,273
|
|||||||||||||||||||||||||||||
Net
loss
|
(2,806,489
|
)
|
(2,806,489
|
)
|
|||||||||||||||||||||||||||
Appropriation
to statutory reserve
|
|
|
|
|
|
|
462,135
|
(462,135
|
)
|
|
-
|
||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
BALANCE,
December 31, 2007
|
2,000,000
|
$
|
2,000
|
17,111,200
|
$
|
17,111
|
$
|
14,741,278
|
$
|
(62,758
|
)
|
$
|
1,652,720
|
$
|
122,271
|
$
|
1,442,602
|
$
|
17,915,224
|
||||||||||||
|
|||||||||||||||||||||||||||||||
Shares
issued for services
|
103,043
|
103
|
115,183
|
115,286
|
|||||||||||||||||||||||||||
Shares
issued for debt settlement
|
210,400
|
210
|
220,710
|
220,920
|
|||||||||||||||||||||||||||
Inducement
cost for debentures converted
|
257,775
|
257,775
|
|||||||||||||||||||||||||||||
Debentures
converted to common stock
|
1,227,503
|
1,228
|
980,775
|
982,003
|
|||||||||||||||||||||||||||
Amortization
of deferred compensation
|
62,758
|
62,758
|
|||||||||||||||||||||||||||||
Foreign
currency translation
|
1,337,825
|
1,337,825
|
|||||||||||||||||||||||||||||
Net
income
|
3,956,310
|
3,956,310
|
|||||||||||||||||||||||||||||
Appropriation
to statutory reserve
|
|
|
|
|
|
|
617,970
|
(617,970
|
)
|
|
-
|
||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
BALANCE,
September 30, 2008, (Unaudited)
|
2,000,000
|
$
|
2,000
|
18,652,146
|
$
|
18,652
|
$
|
16,315,721
|
$
|
-
|
$
|
2,270,690
|
$
|
3,460,611
|
$
|
2,780,427
|
$
|
24,848,101
|
|
Nine months ended
|
||||||
|
September
30,
|
||||||
|
2008
|
2007
|
|||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|||||
Net
income
|
$
|
3,956,310
|
$
|
849,513
|
|||
Adjustments
to reconcile net income to cash used in operating
activities:
|
|||||||
Depreciation
|
330,155
|
179,797
|
|||||
Amortization
|
113,081
|
24,657
|
|||||
Amortization
of deferred financing costs
|
101,815
|
286,132
|
|||||
Amortization
of discount on debentures
|
406,538
|
1,176,618
|
|||||
Amortization
of deferred compensation
|
62,758
|
563,619
|
|||||
Inducement
cost for debentures converted
|
257,775
|
-
|
|||||
Default
premium on debentures
|
490,713
|
-
|
|||||
Issuance
of common stock for services
|
115,286
|
115,763
|
|||||
Inducement
cost for debt settlement
|
42,081
|
-
|
|||||
Change
in operating assets and liabilities
|
|||||||
Accounts
receivable
|
(2,191,545
|
)
|
(1,051,083
|
)
|
|||
Inventories
|
(3,504,274
|
)
|
(2,080,140
|
)
|
|||
Deposits
and prepaid expenses
|
(2,901,353
|
)
|
(1,169,972
|
)
|
|||
Other
receivables
|
(102,306
|
)
|
(1,625,890
|
)
|
|||
Accounts
payable
|
109,968
|
186,357
|
|||||
Accrued
expenses
|
273,498
|
(201,124
|
)
|
||||
Deposits
from customers
|
179,479
|
-
|
|||||
Taxes
payables
|
1,965,966
|
500,991
|
|||||
Other
payables
|
(2,079
|
)
|
5,388
|
||||
Liquidated
damage payable
|
-
|
345,017
|
|||||
Net
cash used in operating activities
|
(296,134
|
)
|
(1,894,357
|
)
|
|||
|
|||||||
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|||||||
Refund
of long term prepayment
|
559,143
|
||||||
Prepay
for potentional acquisition
|
(430,110
|
)
|
-
|
||||
Loans
to third parties
|
(109,930
|
)
|
(553,031
|
)
|
|||
Proceeds
from loans receivable
|
688,176
|
-
|
|||||
Purchase
of plant and equipment
|
(1,622,813
|
)
|
(373,629
|
)
|
|||
Net
cash used in investing activities
|
(915,534
|
)
|
(926,660
|
)
|
|||
|
|||||||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|||||||
Increase
in restricted cash
|
(506
|
)
|
(501
|
)
|
|||
Repayments
to shareholders and directors
|
(492,687
|
)
|
-
|
||||
Proceeds
from shareholders and directors
|
601,686
|
-
|
|||||
Proceeds
from related companies
|
-
|
33,188
|
|||||
Repay
amounts due to related companies
|
(47,965
|
)
|
-
|
||||
Proceeds
from shareholders loans
|
301,077
|
-
|
|||||
Proceeds
from short term loan
|
716,850
|
||||||
Repayments
on short term loan
|
-
|
(39,192
|
)
|
||||
Principle
payment on convertible debenture
|
-
|
(777,512
|
)
|
||||
Repayments
of non-interest bearing loan from third parties
|
-
|
(64,014
|
)
|
||||
Proceeds
from convertible debentures, net of debenture expenses
|
-
|
3,737,250
|
|||||
Net
cash provided by financing activities
|
1,078,455
|
2,889,219
|
|||||
|
|||||||
EFFECT
OF EXCHANGE RATE CHANGES ON CASH
|
47,547
|
1,994
|
|||||
|
|||||||
(DECREASE)
INCREASE IN CASH
|
(85,666
|
)
|
70,196
|
||||
|
|||||||
CASH,
beginning of period
|
771,492
|
192,016
|
|||||
|
|||||||
CASH,
end of period
|
$
|
685,826
|
$
|
262,212
|
|||
|
|||||||
SUPPLEMENTAL
DISCLOSURE INFORMATION
|
|||||||
Interest
paid
|
$
|
12,728
|
$
|
1,694,154
|
|||
Income
taxes paid
|
$
|
740,899
|
$
|
444,205
|
|||
Non-cash
investing and financing transactions
|
|||||||
Warrants
issued for financing services
|
$
|
-
|
$
|
643,277
|
|||
Issuance
of common stock for debt settlement
|
$
|
178,839
|
$
|
-
|
|||
Debentures
converted to common stock
|
$
|
982,003
|
$
|
-
|
·
|
Level
1 inputs to the valuation methodology are quoted prices (unadjusted)
for
identical assets or liabilities in active
markets
|
·
|
Level
2 inputs to the valuation methodology include quoted prices for similar
assets and liabilities in active markets, and inputs that are observable
for the assets or liability, either directly or indirectly, for
substantially the full term of the financial
instruments.
|
·
|
Level
3 inputs to the valuation methodology are unobservable and significant
to
the fair value.
|
a.
|
Credit
sales: Revenue is recognized when the products have been delivered
to the
customers.
|
b.
|
Full
payment before delivering: Revenue is recognized when the products
have
been delivered to customers.
|
|
Three months ended
|
|
Nine months ended
|
|
|||||||||
|
|
September
30, 2008
|
|
September
30, 2007
|
|
September
30, 2008
|
|
September
30, 2007
|
|||||
|
(Unaudited)
|
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
||||||||
Revenues
|
|
|
|
|
|||||||||
Micro-organism
|
$
|
2,411,526
|
$
|
1,467,380
|
$
|
4,352,781
|
$
|
3,506,220
|
|||||
Veterinary
Medications
|
6,785,154
|
3,327,622
|
11,389,155
|
5,211,589
|
|||||||||
Feed
Additives
|
513,980
|
367,562
|
784,161
|
915,359
|
|||||||||
Vaccines
|
340,599
|
285,997
|
689,710
|
557,662
|
|||||||||
Total
Revenues
|
10,051,259
|
5,448,561
|
17,215,807
|
10,190,830
|
|||||||||
|
|||||||||||||
Cost
of Sales
|
|||||||||||||
Micro-organism
|
720,667
|
395,063
|
1,305,793
|
1,189,379
|
|||||||||
Veterinary
Medications
|
3,894,925
|
1,689,614
|
6,607,869
|
2,621,569
|
|||||||||
Feed
Additives
|
212,938
|
152,285
|
339,578
|
503,107
|
|||||||||
Vaccines
|
36,592
|
31,382
|
75,785
|
62,615
|
|||||||||
Total
Cost of Sales
|
4,865,122
|
2,268,344
|
8,329,025
|
4,376,670
|
|||||||||
Gross
Profit
|
$
|
5,186,137
|
$
|
3,180,217
|
$
|
8,886,782
|
$
|
5,814,160
|
|
|
Estimated Useful Life
|
|
|
|
Buildings
|
|
20-40
years
|
|
|
|
Machinery
and equipment
|
|
10
years
|
|
|
|
Computer,
office equipment and furniture
|
|
5
years
|
|
|
|
Automobiles
|
|
5-10
years
|
September 30,
2008
|
December 31,
2007
|
||||||
(Unaudited)
|
|||||||
Funds
received from PRC government
|
$
|
80,516
|
$
|
74,969
|
|||
|
|||||||
(See
Note 12)
|
|
September
30,
2008
|
December 31,
2007
|
|||||
|
(Unaudited)
|
|
|||||
Balance
at the beginning of the period
|
$
|
199,639
|
$
|
14,426
|
|||
Charge
for the period
|
—
|
176,916
|
|||||
Write-off
of accounts receivable against the allowance
|
—
|
—
|
|||||
Foreign
currency translation adjustments
|
13,397
|
8,297
|
|||||
Balance
at the end of the period
|
$
|
213,096
|
$
|
199,639
|
|
September 30,
2008
|
December 31, 2007
|
|||||
|
(Unaudited)
|
|
|||||
|
|
|
|||||
Raw
material
|
$
|
3,132,437
|
$
|
1,761,145
|
|||
|
|||||||
Packing
materials
|
375,072
|
110,020
|
|||||
|
|||||||
Work
in process
|
7,633
|
2,639
|
|||||
Finished
goods
|
2,434,329
|
355,041
|
|||||
|
|||||||
Low
value consumables
|
19,517
|
13,766
|
|||||
|
|||||||
Total
|
$
|
5,968,988
|
$
|
2,242,611
|
|
September 30,
2008
|
December 31, 2007
|
|||||
|
(Unaudited)
|
|
|||||
|
|
|
|||||
Shanxi
Suoang Biotechnological Company, due October 30, 2007, extended to
March
31, 2008, annual interest at 7.0%, secured by unrelated company Shanxi
New
Resource Co.
|
-
|
27,420
|
|||||
|
|||||||
Xi’an
Tiantai Investment Company, due upon demand, minimum annual interest
at
7.2%, unsecured
|
424,270
|
383,880
|
|||||
Xi’an
SilverRiver Automatic Equipment Company, due on March 23, 2008 and
extended to April 2008, annual interest rate 8.4%, unsecured, balance
was
repaid in April 2008
|
-
|
411,300
|
|||||
|
|||||||
Shanxi
Hongye Housing Company, due on demand, non-interest bearing,
unsecured
|
-
|
137,100
|
|||||
|
|||||||
Others,
non-interest bearing, due on demand, unsecured
|
$
|
9,766
|
$
|
9,152
|
|||
|
|||||||
Total
loan receivable
|
$
|
434,036
|
$
|
968,852
|
|
September 30, 2008
|
December 31, 2007
|
|||||
|
(Unaudited)
|
|
|||||
|
|
|
|||||
Building
and improvements
|
$
|
3,833,592
|
$
|
3,592,519
|
|||
|
|||||||
Plant
and machinery
|
3,025,467
|
2,827,591
|
|||||
|
|||||||
Office
equipment
|
188,009
|
167,617
|
|||||
|
|||||||
Vehicles
|
328,248
|
295,995
|
|||||
|
|||||||
Construction
in progress
|
7,528,715
|
5,531,236
|
|||||
|
|||||||
Total
|
14,904,031
|
12,414,958
|
|||||
Less:
accumulated depreciation
|
(999,565
|
)
|
(620,991
|
)
|
|||
|
|||||||
Plant
and equipment , net
|
$
|
13,904,466
|
$
|
11,793,967
|
|
September 30,
2008
|
December 31,
2007
|
|||||
|
(Unaudited)
|
|
|||||
|
|
|
|||||
Equipment
deposit
|
$
|
438,900
|
$
|
411,300
|
|||
|
|||||||
Construction
deposit
|
292,600
|
274,200
|
|||||
|
|||||||
Refundable
deposit for the potential acquisitions
|
438,900
|
534,690
|
|||||
|
|||||||
Total
|
$
|
1,170,400
|
$
|
1,220,190
|
|
2008
|
2007
|
|||||
|
(Unaudited)
|
|
|||||
|
|
|
|||||
Land
use rights
|
$
|
377,820
|
$
|
354,061
|
|||
|
|||||||
Technological
know-how
|
877,800
|
822,600
|
|||||
|
|||||||
Total
|
1,255,620
|
1,176,661
|
|||||
|
|||||||
Less:
accumulated amortization
|
(291,918
|
)
|
(165,425
|
)
|
|||
|
|||||||
Intangible
assets, net
|
$
|
963,702
|
$
|
1,011,236
|
·
|
The
Amended Agreement amends the terms of the Debentures held by the
Participating Purchasers by: (a) changing the conversion price from
$1.00
per share to $0.85 per share; (b) deleting the trading conditions
for
mandatory conversion; (c) granting the Company the right to mandatory
conversion at any time, and (d) allowing the Company to designate
the date
for the mandatory conversion.
|
·
|
The
Amended Agreement amends the terms of the Warrants held by the
Participating Purchasers by: (a) changing the exercise price from
$1.20
per share to $0.95 per share; and (b) granting to the Participating
Purchasers the right to exercise their Warrants on a cashless
basis
|
|
·
|
The
Amended Agreement is deemed to be: (a) the Company’s notice (the
“Conversion Notice”) to require conversion of the entire outstanding
principal of the Debentures held by the Participating Purchasers
and all
accrued but unpaid interest thereto; and (b) the Participating Purchasers’
notice (the “Exercise Notice”) to the Company to exercise all of their
unexercised Warrants on a cashless basis
|
|
·
|
The
Amended Agreement amends the Registration Rights Agreement by waiving
all
outstanding registration damages due to the Purchasers in their entirety.
Because the outstanding principal amounts of the Debentures held
by the
Participating Purchasers, as of the effective date of the Agreement,
total
more than seventy-five percent (75%) of the aggregate outstanding
principal amounts of the outstanding Debentures held by all the Purchasers
on that date, the amendment to the Registration Rights Agreement
binds all
of the Purchasers.
|
·
|
The
Amendment amends the terms of the Debentures held by these two investors
by changing the conversion price from $1.00 per share to $0.80 per
share.
|
·
|
The
Amendment is deemed to be: (a) the Company’s notice (the “Conversion
Notice”) to require conversion of the entire outstanding principal of the
Debentures held by these two investors and all accrued but unpaid
interest
thereto.
|
Outstanding
Warrants
|
Exercisable
Warrants
|
||||||||||||
Exercise
Price
|
Number
|
Average
Remaining
Contractual
Life
|
Average
Exercise
Price
|
Number
|
|||||||||
$1.20
|
975,000
|
1.42
years
|
$
|
1.20
|
975,000
|
||||||||
$1.00
|
570,500
|
3.42
years
|
$
|
1.00
|
570,500
|
||||||||
Total
|
1,545,500
|
1,545,500
|
Outstanding
as of December 31, 2006
|
-
|
|||
Granted
|
4,645,500
|
|||
Forfeited
|
-
|
|||
Exercised
|
3,100,000
|
|||
Outstanding
as of December 31, 2007
|
1,545,500
|
|||
Granted
|
-
|
|||
Forfeited
|
-
|
|||
Exercised
|
-
|
|||
Outstanding
as of September 30, 2008
|
1,545,500
|
|
2008
|
2007
|
|||||
|
(Unaudited)
|
(Unaudited)
|
|||||
Current
PRC income tax expense
|
|
|
|||||
Enterprise
income tax
|
$
|
642,066
|
$
|
415,578
|
2008
|
2007
|
||||||
(Unaudited)
|
(Unaudited)
|
||||||
U.S.
Statutory rates
|
34.0
|
%
|
34.0
|
%
|
|||
Foreign
income not recognized in USA
|
(34.0
|
)
|
(34.0
|
)
|
|||
China
income taxes
|
25.0
|
33.0
|
|||||
China
income tax exemption
|
(10.0
|
)
|
(18.0
|
)
|
|||
Total
provision for income taxes
|
15.0
|
%
|
15.0
|
%
|
|
2008
|
2007
|
|||||
|
(Unaudited)
|
(Unaudited)
|
|||||
Current
PRC income tax expense
|
|
|
|||||
Enterprise
income tax
|
$
|
1,056,506
|
$
|
715,845
|
2008
|
2007
|
||||||
(Unaudited)
|
(Unaudited)
|
||||||
U.S.
Statutory rates
|
34.0
|
%
|
34.0
|
%
|
|||
Foreign
income not recognized in USA
|
(34.0
|
)
|
(34.0
|
)
|
|||
China
income taxes
|
25.0
|
33.0
|
|||||
China
income tax exemption
|
(10.0
|
)
|
(18.0
|
)
|
|||
Total
provision for income taxes
|
15.0
|
%
|
15.0
|
%
|
|
For the three months ended
September 30,
|
For the nine months ended
September 30,
|
|||||||||||
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Net
income for earnings per share
|
$
|
3,466,024
|
$
|
1,071,922
|
$
|
3,956,310
|
$
|
849,513
|
|||||
|
|||||||||||||
Weighted
average shares used in basic computation
|
18,647,042
|
12,865,739
|
18,085,395
|
12,819,290
|
|||||||||
Diluted
effect of stock options and warrants
|
-
|
366,321
|
40,960
|
506,665
|
|||||||||
Weighted
average shares used in diluted computation
|
18,647,042
|
13,232,060
|
18,126,355
|
13,325,955
|
|||||||||
|
|||||||||||||
Earnings
per share:
|
|||||||||||||
Basic
|
$
|
0.19
|
$
|
0.08
|
$
|
0.22
|
$
|
0.07
|
|||||
Diluted
|
$
|
0.19
|
$
|
0.08
|
$
|
0.22
|
$
|
0.06
|
|
September
30,
2008
|
December
31,
2007
|
|||||
|
(Unaudited)
|
|
|||||
Amounts
due from shareholder:
|
|
|
|||||
Mr.
Weibing Lu (1)
|
$
|
-
|
$
|
59,462
|
|||
|
|||||||
Amount
due to shareholder and director:
|
|||||||
Ms.
Aixia Wang (1)
|
$
|
8,778
|
$
|
1,371
|
|||
Mr.
Weibing Lu (1)
|
40,459
|
||||||
Ms.
Aixia Wang (2)
|
43,890
|
-
|
|||||
Mr.
Weibing Lu (2)
|
219,450
|
-
|
|||||
Mr.
Wei Wen (2)
|
43,890
|
-
|
|||||
Mr.
Scott Cramer(1)
|
30,245
|
30,245
|
|||||
Total
|
$
|
386,712
|
$
|
31,616
|
|||
|
|||||||
Amount
due to related companies:
|
|||||||
TianXing
Digital - owned by a director (3)
|
$
|
-
|
$
|
17,137
|
|||
Shanxi
Xingji Electronics Co. - owned by a director's wife (3)
|
4,361
|
32,817
|
|||||
Total
|
$
|
4,361
|
49,954
|
(1)
|
The
related individuals, Weibing Lu, Aixia Wang, and Scott Cramer are
all
shareholders of the Company. Mr. Lu and Mr. Cramer are also the directors
of the Company, with Mr. Lu additionally being the chief executive
office.
The amounts due from Mr. Lu were expense advances for Mr. Lu’s
business-related travels on behalf of Xian Tianxing. Mr. Lu was permitted
to continue drawing on the expense advancement toward his travels
through
the second quarter of 2008, at the end of which Mr. Lu returned to
Xian
Tianxing the then remaining unsubstantiated balance of the advance.
Going
forward, the Company does not intend to provide Mr. Lu or any other
management members with similar type of expense advancement until
such
time that its board of directors, comprising of a majority of independent
directors, shall have determined that such arrangement is appropriate
and/or necessary for the Company, and have adopted specific policy
and
procedure accordingly. The amounts due to Mr. Lu, Ms. Wang and Mr.
Cramer
were cash advances to facilitate Xian Tianxing operations or expenses
paid
by these individuals on behalf of the Company. These balances are
non-interest bearing, unsecured, due on demand, and the ultimate
manner of
settlement is in cash.
|
(2)
|
The
related individuals, Weibing Lu, Aixia Wang, and Wei Wen are all
shareholders of the Company. Mr. Lu and Mr. Wen are also the directors
of
the Company, with Mr. Lu additionally being the chief executive officer.
These individuals obtained personal loans from the bank and advanced
the
cash to facilitate Company operations. The short-term loans with
balances
of $175,560 and $43,890 from Mr. Lu bear annual interest at 7.47%
and
$8.44%, respectively, and are due on December 30, 2008 and May 29,
2009,
respectively. The short-term loans from Ms. Wang and Mr. Wen
each have a balance of $43,890, bear annual interest at 8.44%,
and are both due on May 29, 2009.
|
(3)
|
Shanxi
Xinji Electronics Company is owned by the wife of Mr. Lu and Tianxing
Digital Co. Ltd. is owned by Mr. Lu. The amount due to Shanxi Xinji
Electronics Co. Ltd. and Tianxing Digital Co., Ltd are short term
cash
transfers for business operations, non-interest bearing, unsecured,
and
payable upon demand. The ultimate manner of settlement is in
cash.
|
Three
months ending December 31, 2008
|
$
|
14,488
|
||
Year
ending December 31, 2009
|
57,950
|
|||
Year
ending December 31, 2010
|
57,950
|
|||
Year
ending December 31, 2011
|
57,950
|
|||
Year
ending December 31, 2012
|
34,547
|
|||
Thereafter
|
120,733
|
|||
|
$
|
343,618
|
|
2007
|
2006
|
|||||
ASSETS
|
|
|
|||||
|
|
|
|||||
CURRENT
ASSETS:
|
|
|
|||||
Cash
|
$
|
771,492
|
$
|
192,016
|
|||
Restricted
cash
|
74,969
|
69,610
|
|||||
Accounts
receivable, net of allowance for doubtful accounts of $199,639 and
$14,426
as of December 31, 2007 and 2006, respectively.
|
1,356,094
|
131,599
|
|||||
Inventories
|
2,242,611
|
528,566
|
|||||
Deposits
and prepaid expenses
|
806,657
|
29,944
|
|||||
Loans
receivable
|
968,852
|
8,558
|
|||||
Other
receivables
|
43,800
|
38,881
|
|||||
Other
receivables-shareholder
|
59,462
|
-
|
|||||
Total
current assets
|
6,323,937
|
999,174
|
|||||
|
|||||||
PLANT
AND EQUIPMENT, net
|
11,793,967
|
10,910,948
|
|||||
|
|||||||
OTHER
ASSETS:
|
|||||||
Long
term prepayment
|
1,220,190
|
-
|
|||||
Deferred
financing costs
|
101,815
|
-
|
|||||
Intangible,
net
|
1,011,236
|
336,852
|
|||||
Total
other assets
|
2,333,241
|
336,852
|
|||||
Total
assets
|
$
|
20,451,145
|
$
|
12,246,974
|
|||
|
|||||||
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
|||||||
|
|||||||
CURRENT
LIABILITIES:
|
|||||||
Interest-bearing
short-term loan
|
$
|
-
|
$
|
38,460
|
|||
Non-interest
bearing loan from third party
|
-
|
62,818
|
|||||
Accounts
payable
|
126,754
|
71,223
|
|||||
Accrued
expenses
|
502,871
|
523,892
|
|||||
Deposits
from customers
|
61,706
|
-
|
|||||
Taxes
payable
|
568,797
|
218,231
|
|||||
Other
payables
|
81,221
|
607,595
|
|||||
Amount
due to related companies
|
49,954
|
16,025
|
|||||
Amount
due to shareholders and directors
|
31,616
|
-
|
|||||
Total
current liabilities
|
1,422,919
|
1,538,244
|
|||||
|
|||||||
OTHER
LIABILITIES:
|
|||||||
Deferred
government grant
|
1,028,250
|
961,500
|
|||||
Convertible
debenture, net of $398,171 discount
|
84,752
|
-
|
|||||
Total
other liabilities
|
1,113,002
|
961,500
|
|||||
Total
liabilities
|
2,535,921
|
2,499,744
|
|||||
|
|||||||
CONTINGENT
LIABILITIES
|
-
|
-
|
|||||
|
|||||||
SHAREHOLDERS'
EQUITY:
|
|||||||
Preferred
stock, $0.001 par value, 50,000,000 shares authorized, 2,000,000
series
"A" shares issued and outstanding as of December 31, 2007 and 2006,
respectively; Nil series "B" shares issued and outstanding as of
December
31, 2007 and 2006, respectively.
|
2,000
|
2,000
|
|||||
Common
stock, $0.001 par value, 50,000,000 shares authorized as of December
31,
2007 and 2006, respectively; 17,111,200 and 12,795,549 shares issued
and
outstanding as of December 31, 2007 and 2006,
respectively.
|
17,111
|
12,795
|
|||||
Paid-in-capital
|
14,741,278
|
6,246,325
|
|||||
Deferred
compensation
|
(62,758
|
)
|
(705,877
|
)
|
|||
Statutory
reserves
|
1,652,720
|
779,624
|
|||||
Retained
earnings
|
122,271
|
2,952,343
|
|||||
Accumulated
other comprehensive income
|
1,442,602
|
460,020
|
|||||
Total
shareholders' equity
|
17,915,224
|
9,747,230
|
|||||
Total
liabilities and shareholders' equity
|
$
|
20,451,145
|
$
|
12,246,974
|
|
2007
|
2006
|
|||||
REVENUE
|
$
|
15,056,828
|
$
|
9,796,324
|
|||
COST
OF SALES
|
6,712,365
|
5,420,652
|
|||||
|
|||||||
GROSS
PROFIT
|
8,344,463
|
4,375,672
|
|||||
|
|||||||
OPERATING
EXPENSES
|
|||||||
Research
and development
|
268,320
|
131,371
|
|||||
Selling
expenses
|
739,422
|
475,504
|
|||||
General
and administrative expenses
|
2,438,995
|
2,083,458
|
|||||
|
|||||||
Total
operating expenses
|
3,446,737
|
2,690,333
|
|||||
|
|||||||
INCOME
FROM OPERATIONS
|
4,897,726
|
1,685,339
|
|||||
|
|||||||
OTHER
EXPENSE (INCOME)
|
|||||||
Other
expense
|
3,651
|
3,478
|
|||||
Interest
income
|
(14,611
|
)
|
-
|
||||
Interest
expense
|
4,924,493
|
11,768
|
|||||
Inducement
cost for debentures converted
|
634,450
|
-
|
|||||
Inducement
cost for warrants exercised
|
279,547
|
-
|
|||||
Total
other expense
|
5,827,530
|
15,246
|
|||||
|
|||||||
INCOME
(LOSS) BEFORE PROVISION FOR INCOME TAXES
|
(929,804
|
)
|
1,670,093
|
||||
|
|||||||
PROVISION
FOR INCOME TAXES
|
1,027,172
|
494,951
|
|||||
|
|||||||
NET
INCOME (LOSS)
|
(1,956,976
|
)
|
1,175,142
|
||||
|
|||||||
OTHER
COMPREHENSIVE INCOME :
|
|||||||
Foreign
currency translation adjustment
|
982,582
|
298,675
|
|||||
COMPREHENSIVE
INCOME (LOSS)
|
$
|
(974,394
|
)
|
$
|
1,473,817
|
||
|
|||||||
EARNINGS
PER SHARE
|
|||||||
Basic
|
$
|
(0.15
|
)
|
$
|
0.11
|
||
Diluted
|
$
|
(0.15
|
)
|
$
|
0.09
|
||
WEIGHTED
AVERAGE NUMBER OF COMMON SHARES
|
|||||||
Basic
|
13,453,543
|
11,144,153
|
|||||
Diluted
|
13,453,543
|
12,498,386
|
|
|
|
|
|
Retained earnings
|
|
Accumulated
other
|
|
|
|
|||||||||||||||||||||
|
|
Preferred stock
|
|
Common stock
|
Paid-in
|
|
Deferred
|
|
Statutory
|
|
|
|
comprehensive
|
|
|
||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
capital
|
|
Compensation
|
|
reserves
|
|
Unrestricted
|
|
income
|
Totals
|
|||||||||||||
BALANCE,
December 31, 2005
|
50,000,000
|
$
|
50,000
|
1,260,651
|
$
|
1,261
|
$
|
4,301,747
|
$
|
-
|
$
|
364,460
|
$
|
2,192,365
|
$
|
161,345
|
$
|
7,071,178
|
|||||||||||||
Shares
conversion
|
(48,000,000
|
)
|
(48,000
|
)
|
10,745,548
|
10,745
|
37,255
|
-
|
|||||||||||||||||||||||
Shares
issued for services
|
789,350
|
789
|
1,907,323
|
(1,908,112
|
)
|
-
|
|||||||||||||||||||||||||
Amortization
of deferred compensation
|
1,202,235
|
1,202,235
|
|||||||||||||||||||||||||||||
Foreign
currency translation
|
298,675
|
298,675
|
|||||||||||||||||||||||||||||
Net
income
|
1,175,142
|
1,175,142
|
|||||||||||||||||||||||||||||
Appropriation
to statutory reserve
|
|
|
|
|
|
|
415,164
|
(415,164
|
)
|
|
-
|
||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
BALANCE,
December 31, 2006
|
2,000,000
|
$
|
2,000
|
12,795,549
|
$
|
12,795
|
$
|
6,246,325
|
$
|
(705,877
|
)
|
$
|
779,624
|
$
|
2,952,343
|
$
|
460,020
|
$
|
9,747,230
|
||||||||||||
Shares
issued for services
|
78,750
|
79
|
115,684
|
115,763
|
|||||||||||||||||||||||||||
Beneficial
conversion feature of debentures
|
2,130,575
|
2,130,575
|
|||||||||||||||||||||||||||||
Warrants
issued to debenture holders
|
1,944,425
|
1,944,425
|
|||||||||||||||||||||||||||||
Warrants
issued to placement agent
|
643,277
|
643,277
|
|||||||||||||||||||||||||||||
Inducement
cost for debentures converted
|
634,450
|
634,450
|
|||||||||||||||||||||||||||||
Inducement
cost for warrants exercised
|
279,547
|
279,547
|
|||||||||||||||||||||||||||||
Debentures
converted to common stock
|
3,278,720
|
3,279
|
2,747,953
|
2,751,232
|
|||||||||||||||||||||||||||
Cashless
exercise of warrants
|
958,181
|
958
|
(958
|
)
|
-
|
||||||||||||||||||||||||||
Amortization
of deferred compensation
|
643,119
|
643,119
|
|||||||||||||||||||||||||||||
Foreign
currency translation
|
982,582
|
982,582
|
|||||||||||||||||||||||||||||
Net
income
|
(1,956,976
|
)
|
(1,956,976
|
)
|
|||||||||||||||||||||||||||
Appropriation
to statutory reserve
|
|
|
|
|
|
|
873,096
|
(873,096
|
)
|
|
-
|
||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
BALANCE,
December 31, 2007
|
2,000,000
|
$
|
2,000
|
17,111,200
|
$
|
17,111
|
$
|
14,741,278
|
$
|
(62,758
|
)
|
$
|
1,652,720
|
$
|
122,271
|
$
|
1,442,602
|
$
|
17,915,224
|
|
2007
|
2006
|
|||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|||||
Net
income (loss)
|
$
|
(1,956,976
|
)
|
$
|
1,175,142
|
||
Adjustments
to reconcile net income (loss) to cash provided by operating
activities:
|
|||||||
Depreciation
|
281,894
|
84,365
|
|||||
Amortization
|
33,135
|
35,405
|
|||||
Amortization
of deferred financing costs
|
879,212
|
-
|
|||||
Amortization
of discount on debentures
|
3,716,243
|
-
|
|||||
Amortization
of deferred compensation
|
643,119
|
1,202,235
|
|||||
Inducement
cost for debentures converted
|
634,450
|
-
|
|||||
Inducement
cost for warrants exercised
|
279,547
|
-
|
|||||
Issuance
of common stock for service
|
115,763
|
-
|
|||||
Bad
debt expense
|
238,094
|
(57,187
|
)
|
||||
Change
in operating assets and liabilities
|
|||||||
Accounts
receivable
|
(1,405,316
|
)
|
178,774
|
||||
Inventories
|
(1,610,916
|
)
|
(339,811
|
)
|
|||
Deposits
and prepaid expenses
|
(743,955
|
)
|
(13,958
|
)
|
|||
Other
receivables
|
(10,921
|
)
|
(9,721
|
)
|
|||
Accounts
payable
|
48,582
|
59,947
|
|||||
Accrued
expenses
|
(34,166
|
)
|
376,131
|
||||
Deposits
from customers
|
59,262
|
-
|
|||||
Taxes
payables
|
322,131
|
(1,620,586
|
)
|
||||
Other
payables
|
(546,037
|
)
|
529,818
|
||||
Net
cash provided by operating activities
|
943,145
|
1,600,554
|
|||||
|
|||||||
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|||||||
Loan
to third parties
|
(912,901
|
)
|
-
|
||||
Proceeds
from loans receivable
|
-
|
264,953
|
|||||
Long
term prepayment
|
(1,171,863
|
)
|
-
|
||||
Purchase
of intangible assets
|
(658,350
|
)
|
-
|
||||
Purchase
of plant and equipment
|
(402,470
|
)
|
(2,098,659
|
)
|
|||
Net
cash used in investing activities
|
(3,145,584
|
)
|
(1,833,706
|
)
|
|||
|
|||||||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|||||||
Increase
in restricted cash
|
(505
|
)
|
(5,397
|
)
|
|||
Advances
from shareholders and directors
|
1,170,944
|
124,523
|
|||||
Repay
amounts due to shareholders and directors
|
(1,198,791
|
)
|
(79,674
|
)
|
|||
Proceeds
from related companies
|
27,633
|
594,448
|
|||||
Repay
amounts due to related companies
|
-
|
(9,292
|
)
|
||||
Payments
on non-interest bearing loans from third parties
|
(64,518
|
)
|
(364,906
|
)
|
|||
Principal
payments on short-term loan, interest bearing
|
(39,501
|
)
|
-
|
||||
Proceeds
from government subsidies
|
-
|
125,570
|
|||||
Proceeds
from convertible debentures, net of debenture expenses
|
3,737,250
|
-
|
|||||
Payments
on convertible debenture
|
(880,259
|
)
|
-
|
||||
Net
cash provided by financing activities
|
2,752,253
|
385,272
|
|||||
|
|||||||
EFFECT
OF EXCHANGE RATE CHANGES ON CASH
|
29,662
|
1,398
|
|||||
|
|||||||
INCREASE
IN CASH
|
579,476
|
153,518
|
|||||
|
|||||||
CASH,
beginning of year
|
192,016
|
38,498
|
|||||
|
|||||||
CASH,
end of year
|
$
|
771,492
|
$
|
192,016
|
|||
|
|||||||
SUPPLEMENTAL
DISCLOSURE INFORMATION
|
|||||||
Interest
paid
|
$
|
2,817
|
$
|
4,121
|
|||
Income
taxes paid
|
$
|
864,392
|
$
|
853,656
|
|||
Non-cash
investing and financing transactions
|
|||||||
Stocks
issued for services
|
$
|
115,763
|
$
|
1,908,112
|
|||
Warrants
issued for services
|
$
|
643,277
|
$
|
-
|
|||
Inducement
cost for debentures converted
|
$
|
634,450
|
$
|
-
|
|||
Inducement
cost for warrants exercised
|
$
|
279,547
|
$
|
-
|
|||
Debentures
converted to common stock
|
$
|
2,751,232
|
$
|
-
|
|
a.
|
Credit
sales: Revenue is recognized when the products have been delivered
to the
customers.
|
|
b.
|
Full
payment before delivering: Revenue is recognized when the products
have
been delivered to customers.
|
December 31, 2007
|
December 31, 2006
|
||||||
Revenues
|
|||||||
Micro-organism
|
$
|
4,271,139
|
$
|
4,337,562
|
|||
Veterinary
Medications
|
9,003,400
|
3,825,079
|
|||||
Feed
Additives
|
971,019
|
927,424
|
|||||
Vaccines
|
811,270
|
706,259
|
|||||
Total
Revenues
|
15,056,828
|
9,796,324
|
|||||
|
|||||||
Cost
of Sales
|
|||||||
Micro-organism
|
1,416,550
|
2,161,898
|
|||||
Veterinary
Medications
|
4,654,347
|
2,546,627
|
|||||
Feed
Additives
|
549,714
|
629,075
|
|||||
Vaccines
|
91,754
|
83,052
|
|||||
Total
Cost of Sales
|
6,712,365
|
5,420,652
|
|||||
Gross
Profit
|
$
|
8,344,463
|
$
|
4,375,672
|
|
|
Estimated Useful Life
|
|
|
Buildings
|
|
20-40
years
|
|
|
Machinery
and equipment
|
|
10
years
|
|
|
Computer,
office equipment and furniture
|
|
5
years
|
|
|
Automobiles
|
|
5-10
years
|
|
|
2007
|
2006
|
|||||
Funds
received from PRC government
|
$
|
74,969
|
$
|
69,610
|
|
December 31,
2007
|
December 31,
2006
|
|||||
|
|
|
|||||
Balance
at the beginning of the period
|
$
|
14,426
|
$
|
71,613
|
|||
Charge
for the period
|
176,916
|
(58,390
|
)
|
||||
Write-off
of accounts receivable against the allowance
|
—
|
—
|
|||||
Foreign
currency translation adjustments
|
8,297
|
1,203
|
|||||
Balance
at the end of the period
|
$
|
199,639
|
$
|
14,426
|
|
2007
|
2006
|
|||||
Raw
material
|
$
|
1,761,145
|
$
|
190,926
|
|||
Packing
materials
|
110,020
|
97,002
|
|||||
Work
in process
|
2,639
|
-
|
|||||
Finished
goods
|
355,041
|
232,242
|
|||||
Low
value consumables
|
13,766
|
8,396
|
|||||
Total
|
$
|
2,242,611
|
$
|
528,566
|
|
2007
|
2006
|
|||||
Others,
non-interest bearing, unsecured, due on demand
|
$
|
9,152
|
$
|
8,558
|
|||
|
|||||||
Shanxi
Suoang Biotechnological Company, due October 30, 2007, extended to
March
31, 2008, annual interest at 7.0%, secured by unrelated company Shanxi
New
Resource Co.
|
27,420
|
-
|
|||||
|
|||||||
Xi’an
Tiantai Investment Company, due July 31, 2008 (or upon demand), minimum
annual interest at 7.2%, unsecured
|
383,880
|
-
|
|||||
|
|||||||
Xi’an
SilverRiver Automatic Equipment Company, due on March 23, 2008, Annual
interest rate 0.7%, unsecured.
|
411,300
|
-
|
|||||
|
|||||||
Shanxi
Hongye Housing Company, due on demand, non-interest
bearing.
|
137,100
|
-
|
|||||
Total
loan receivable
|
$
|
968,852
|
$
|
8,558
|
|
2007
|
2006
|
|||||
Building
and improvements
|
$
|
3,592,519
|
$
|
351,425
|
|||
Plant
and machinery
|
2,827,591
|
270,621
|
|||||
Office
equipment
|
167,617
|
140,591
|
|||||
Vehicles
|
295,995
|
128,134
|
|||||
Construction
in progress
|
5,531,236
|
10,326,391
|
|||||
Total
|
12,414,958
|
11,217,162
|
|||||
Less:
accumulated depreciation
|
(620,991
|
)
|
(306,214
|
)
|
|||
Plant
and equipment , net
|
$
|
11,793,967
|
$
|
10,910,948
|
|
2007
|
2006
|
|||||
Equipment
deposit
|
$
|
411,300
|
$
|
-
|
|||
Construction
deposit
|
274,200
|
||||||
Refundable
deposit for the potential acquisition of a veterinary
company
|
534,690
|
-
|
|||||
Total
|
$
|
1,220,190
|
$
|
-
|
|
2007
|
2006
|
|||||
Land
use rights
|
$
|
354,061
|
$
|
331,077
|
|||
Technological
know-how
|
822,600
|
128,100
|
|||||
Total
|
1,176,661
|
459,177
|
|||||
Less:
accumulated amortization
|
(165,425
|
)
|
(122,325
|
)
|
|||
Intangible
assets, net
|
$
|
1,011,236
|
$
|
336,852
|
|
·
|
The
Amended Agreement amends the terms of the Debentures held by the
Participating Purchasers by: (a) changing the Conversion Price from
$1.00
per share to $0.85 per share; (b) deleting the Trading Conditions
for
Mandatory Conversion; (c) granting the Company the right to Mandatory
Conversion at any time, and (d) allowing the Company to designate
the date
for the Mandatory Conversion.
|
|
·
|
The
Amended Agreement amends the terms of the Warrants held by the
Participating Purchasers by: (a) changing the Exercise Price from
$1.20
per share to $0.95 per share; and (b) granting to the Participating
Purchasers the right to exercise their Warrants on a cashless
basis
|
|
|
|
|
·
|
The
Amended Agreement is deemed to be: (a) the Company’s notice (the
“Conversion Notice”) to require conversion of the entire outstanding
principal of the Debentures held by the Participating Purchasers
and all
accrued but unpaid interest thereto; and (b) the Participating Purchasers’
notice (the “Exercise Notice”) to the Company to exercise all of their
unexercised Warrants on a cashless basis
|
|
|
|
|
·
|
The
Amended Agreement amends the Registration Rights Agreement by waiving
all
outstanding Registration Damages due to the Purchasers in their entirety.
Because the outstanding principal amounts of the Debentures held
by the
Participating Purchasers, as of the effective date of the Agreement,
total
more than seventy-five percent (75%) of the aggregate outstanding
principal amounts of the outstanding Debentures held by all the Purchasers
on that date, the amendment to the Registration Rights Agreement
binds all
of the Purchasers.
|
Principal repayment Amount
|
||||
2008
|
$
|
414,990
|
||
2009
|
67,933
|
|||
Thereafter
|
-
|
|||
$
|
482,923
|
Outstanding Warrants
|
Exercisable Warrants
|
||||||||||||
Exercise
Price
|
Number |
Average
Remaining
Contractual
Life
|
Average
Exercise
Price
|
Number | |||||||||
$1.20
|
975,000
|
2.16
years
|
$
|
1.20
|
975,000
|
||||||||
$1.00
|
570,500
|
4.16
years
|
$
|
1.00
|
570,000
|
||||||||
Total
|
1,545,500
|
1,545,500
|
Outstanding
as of December 31, 2005
|
-
|
|||
Granted
|
-
|
|||
Forfeited
|
-
|
|||
Exercised
|
-
|
|||
Outstanding
as of December 31, 2006
|
-
|
|||
Granted
|
4,645,500
|
|||
Forfeited
|
-
|
|||
Exercised
|
3,100,000
|
|||
Outstanding
as of December 31, 2007
|
1,545,500
|
|
a.
|
The
new standard EIT rate of 25% will replace the 33% rate currently
applicable to both DES and FIEs, except for High Tech companies who
pays a
reduced rate of 15%;
|
|
b.
|
Companies
established before March 16, 2007 will continue to enjoy tax holiday
treatment approved by local government for a grace period of either
for
the next 5 years or until the tax holiday term is completed, whichever
is
sooner.
|
|
2007
|
2006
|
|||||
Current
PRC income tax expense
|
|
|
|||||
Enterprise
income tax
|
$
|
1,027,172
|
$
|
494,951
|
2007
|
2006
|
||||||
U.S.
Statutory rates
|
34.0
|
%
|
34.0
|
%
|
|||
Foreign
income not recognized in USA
|
(34.0
|
)
|
(34.0
|
)
|
|||
China
income taxes
|
33.0
|
33.0
|
|||||
China
income tax exemption
|
(18.0
|
)
|
(18.0
|
)
|
|||
Total
provision for income taxes
|
15.0
|
%
|
15.0
|
%
|
2007
|
2006
|
||||||
Net income for earnings per share |
$
|
(1,956,976
|
)
|
$
|
1,175,142
|
||
Weighted
average shares used in basic computation
|
13,453,543
|
11,144,153
|
|||||
Diluted
effect of warrants (treasury method)
|
-
|
1,354,233
|
|||||
Weighted
average shares used in diluted computation
|
13,453,543
|
12,498,386
|
|||||
|
|||||||
Earnings
per share
|
|||||||
Basic
|
$
|
(0.15
|
)
|
$
|
0.11
|
||
Diluted
|
$
|
(0.15
|
) |
$
|
0.09
|
|
|
2007
|
|
2006
|
|
||
Amounts
due from shareholder:
|
|
|
|
|
|
Mr.
Weibing Lu (1)
|
|
$
|
59,462
|
|
$
|
-
|
|
|
|
|
|
|
|
||
Amount
due to shareholder and director:
|
|
|
|
|
|
||
Ms.
Aixia Wang (1)
|
|
$
|
1,371
|
|
|
|
|
Mr.
Scott Cramer (1)
|
|
|
30,245
|
|
|
-
|
|
Total
|
|
$
|
31,616
|
|
$
|
-
|
|
|
|
|
|
|
|
||
Amount
due to related companies:
|
|
|
|
|
|
||
TianXing
Digital Co., Ltd. (2)
|
|
$
|
17,137
|
|
$
|
16,025
|
|
Shanxi
Xingji Electronics Co. Ltd. (2)
|
|
|
32,817
|
|
|
-
|
|
Total
|
|
$
|
49,954
|
|
|
16,025
|
|
(1)
|
The
related individuals, Weibing Lu, Aixia Wang, and Scott Cramer are
all
shareholders of the Company. Mr. Lu and Mr. Cramer are also the directors
of the Company, with Mr. Lu additionally being the chief executive
office.
The amounts due from Mr. Lu were expense advances for Mr. Lu’s business
related travels. The amounts due to Ms. Wang and Ms. Cramer were
cash
advances to facilitate Company operations or expenses paid by these
individuals on behalf of the Company. These balances are non-interest
bearing, unsecured, due on demand, and the ultimate manner of settlement
is in cash or in exchange for office premises
rental.
|
(2)
|
Shanxi
Xinji Electronics Company is owned by the wife of Mr. Lu and Tianxing
Digital Co. Ltd. is owned by Mr. Lu. The amount due to Shanxi Xingji
Electronics Co. Ltd. and Tianxing Digital Co., Ltd are short term
cash
transfers for business operations, non-interest bearing, unsecured,
and
payable upon demand. The ultimate manner of settlement is in
cash.
|
|
2007
|
|
||
2008
|
|
$
|
34,789
|
|
2009
|
|
|
35,673
|
|
2010
|
|
|
35,673
|
|
2011
|
|
|
35,673
|
|
2012
|
|
|
13,294
|
|
Thereafter
|
|
|
28,533
|
|
|
|
$
|
183,635
|
|
(b) |
Legal
proceedings
|
(c)
|
Ownership
of leasehold property
|
|
(1)
|
Our
manufacturing facilities in Huxian, Xi’an, Shaanxi Province, People’s
Republic of China.
|
|
(2)
|
Water
purification equipment at our Huxian manufacturing
plant.
|
|
(3)
|
A
technician performing ultra-sonic cleansing of glass tubes at our
Huxian
manufacturing plant.
|
|
$
|
826
|
|
|
FINRA
Filing Fees
|
|
$
|
3,000
|
|
Printing
Fees
|
|
$
|
25,000
|
|
Accounting
Fees and Expenses
|
|
$
|
50,000
|
|
Legal
Fees and Expenses
|
|
$
|
100,000
|
|
Miscellaneous
|
|
$
|
10,000
|
|
|
|
|
|
|
Total
|
|
$
|
188,826
|
*
|
|
Description
|
|
1.1
|
|
Form
of Underwriting Agreement *
|
|
|
|
2.1
|
|
Share
Purchase Agreement by and between The Cyber Group Network, Inc.
and Howard
L. Allen and Donald G. Jackson (stockholders of Hollywood Entertainment
Network, Inc.) dated May 12, 2000 (1 )
|
|
|
|
|
Plan
of Merger Agreement between The Cyber Group Network Corp. and CGN
Acquisitions Corporation dated December 7, 2000 (2 )
|
|
|
|
|
2.3
|
|
Share
Exchange Agreement between The Cyber Group Network Corporation,
R. Scott
Cramer, Steve Lowe, David Wassung and Skystar Bio-Pharmaceutical,
and the
Skystar Stockholders dated September 20, 2005 (3 )
|
|
|
|
3.1
|
|
Charter
of The Cyber Group Network Corporation as filed with the State
of Nevada
(4 )
|
|
|
|
3.2
|
|
Certificate
of Amendment and Certificate of Change (8)
|
|
|
|
3.3
|
|
Certificate
of Amendment to Increase Number of Authorized Shares of Common
Stock
(19)
|
|
|
|
3.4
|
|
Amended
and Restated Bylaws of Skystar Bio-Pharmaceutical Company
(20)
|
|
|
|
3.5
|
|
Certificate
of Designation of Series B Convertible Preferred Stock
(4)
|
|
|
|
4.1
|
|
Form
of Common Stock Certificate (18)
|
|
|
|
4.2
|
|
Form
of Class A Convertible Debenture (9)
|
|
|
|
4.3
|
|
Form
of Class B Convertible Debenture (9)
|
|
|
|
4.4
|
|
Form
of Class A Warrant (9)
|
|
|
|
4.5
|
|
Form
of Class B Warrant (9)
|
|
|
|
4.6
|
|
Form
of Common Stock Purchase Option to be granted to the representative
of the
underwriters (22)
|
|
|
|
5.1
|
|
Opinion
of Richardson & Patel LLP *
|
|
|
|
10.1
|
|
Form
of Securities Purchase Agreement, dated as of February 26, 2007
by and
among the Company and the Purchasers (9 )
|
|
|
|
|
Form
of Registration Rights Agreement, dated as of February 26, 2007
by and
among the Company and the Purchasers (9 )
|
|
|
|
|
10.3
|
|
Form
of Company Principal Lockup Agreement in connection with the Securities
Purchase Agreement dated as of February 26, 2007 (9)
|
|
|
|
10.4
|
|
Form
of the Amendment, Exchange and Waiver Agreement between Skystar
Bio-Pharmaceutical Company and the Participating Purchasers dated
November
9, 2007 (12)
|
|
|
|
10.5
|
|
Form
of the Amendment and Waiver Agreement between Skystar Bio-Pharmaceutical
Company and two institutional and accredited investors dated March
31,
2008 (15)
|
10.6
|
|
Form
of 6-month Lock-up Agreement *
|
|
|
|
|
|
10.7
|
|
Consulting
Services Agreement between Skystar Bio-Pharmaceutical (Cayman)
Holdings,
Co., Ltd. (“Skystar Cayman”) and Xian Tianxing Bio-Pharmaceutical Co.,
Ltd. (“Xian Tianxing”) dated October 28, 2005 (4
)
|
10.8
|
|
Equity
Pledge Agreement among Skystar Cayman, Xian Tianxing and Xian Tianxing’s
Majority Stockholders dated October 28, 2005 (4
)
|
10.9
|
|
Operating
Agreement among Skystar Cayman, Xian Tianxing, Xian Tianxing’s Majority
Stockholders, and Weibing Lu dated October 28, 2005 (4
)
|
|
|
|
10.10
|
|
Proxy
Agreement among Skystar Cayman, Xian Tianxing, Xian Tianxing’s Majority
Stockholders and Weibing Lu dated October 28, 2005 (4 )
|
|
|
|
10.11
|
|
Option
Agreement among Skystar Cayman, Xian Tianxing, Xian Tianxing Majority
Stockholders and Weibing Lu dated October 28, 2005 (4
)
|
10.12
|
|
Amendment
to Consulting Services Agreement among Skystar Cayman, Xian Tianxing
and
Sida Biotechnology (Xian) Co., Ltd. (“Sida”) dated March 10, 2008
(13)
|
|
|
|
10.13
|
|
Amendment
to Equity Pledge Agreement among Skystar Cayman, Xian Tianxing,
Xian
Tianxing’s Majority Stockholders, and Sida dated March 10, 2008
(13)
|
|
|
|
10.14
|
|
Agreement
to Transfer of Operating Agreement among Skystar Cayman, Xian Tianxing,
Xian Tianxing’s Majority Stockholders, Weibing Lu and Sida dated March 10,
2008 (13)
|
|
|
|
10.15
|
|
Designation
Agreement among Skystar Cayman, Xian Tianxing, Xian Tianxing’s Majority
Stockholders, Weibing Lu and Sida dated March 10, 2008
(13)
|
|
|
|
10.16
|
|
Agreement
to Transfer of Option Agreement among Skystar Cayman, Xian Tianxing,
Xian
Tianxing Majority Stockholders, Weibing Lu and Sida dated March
10, 2008
(13)
|
|
|
|
10.17
|
|
Employment
Agreement with Weibing Lu dated May 5, 2008 (16)
|
|
|
|
10.18
|
|
Loanout
Agreement with Worldwide Officers, Inc. with respect to the services
of
Bennet Tchaikovsky, our Chief Financial Officer, dated May 5, 2008
(16)
|
|
|
|
10.19
|
|
Form
of Director Offer Letter with Mr. Qiang Fan and Mr. Winston Yen
(20)
|
|
|
|
10.20
|
|
Form
of Director Offer Letter with Mr. Chengtun Qu and Mr. Shouguo Zhao
(20)
|
|
|
|
16.1
|
|
Letter
from Weinberg & Company, P.A. (6 )
|
|
|
|
16.2
|
|
Letter
from GC Alliance Limited (7)
|
|
|
|
16.3
|
|
Letter
from Moore Stephens Wurth Frazer & Torbet LLP (10 )
|
|
|
|
16.4
|
|
Letter
from Schwartz Levitsky Feldman LLP (11 )
|
|
|
|
23.1
|
|
Consent
of Moore Stephens Worth Frazer and Torbet LLP *
|
|
|
|
23.2
|
|
Consent
of Richardson & Patel LLP (17)
|
|
|
|
24.1
|
|
Power
of Attorney (included as part of the signature page to the registration
statement) *
|
|
|
|
99.1
|
|
Legal
Opinion from Allbright Law Offices regarding, among other things,
the
contractual arrangements Skystar Cayman entered into with Xian
Tianxing
and its stockholders, dated November 3, 2005 (18)
|
|
|
|
99.2
|
|
Legal
Opinion from Allbright Law Offices regarding the transfer of the
contractual arrangements from Skystar Cayman to Sida, dated April
29, 2008
(18)
|
|
|
|
99.3
|
|
Lease
Agreement between Xian Tianxing and Weibing Lu dated June 1, 2007
(14)
|
|
|
|
99.4
|
|
Lease
Agreement between Shanghai Siqiang Biotechnological Co., Ltd. and
Weibing
Lu dated June 17, 2007 (18)
|
|
|
|
99.5
|
|
Summary
of Research Arrangement between Shanghai Poultry Verminosis Institute
and
Xian Tianxing (18)
|
|
|
|
99.6
|
|
Cooperation
Agreement between Shaanxi Microbial Institute and Xian Tianxing
(18)
|
*
|
Filed
herewith.
|
|
(1)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
June 1, 2000.
|
|
(2)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K/A filed on
January 12, 2001.
|
|
(3)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
September 26, 2005.
|
|
(4)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
November 14, 2005.
|
(5)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
December 21, 2005.
|
|
(6)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K/A filed on
January 27, 2006.
|
|
(7)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K/A filed on
March 3, 2006.
|
|
(8)
|
Incorporated
by reference from the Registrant’s Annual Report on Form 10-KSB filed on
April 17, 2006.
|
|
(9)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K/A filed on
March 5, 2007.
|
|
(10)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K/A filed on
March 8, 2007.
|
|
(11)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
April 30, 2007.
|
|
(12)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
December 11, 2007.
|
|
(13)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
March 11, 2008.
|
|
(14)
|
Incorporated
by reference from the Registrant’s Annual Report on Form 10-K filed on
April 2, 2008.
|
|
(15)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
April 23, 2008.
|
|
(16)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on May
7, 2008.
|
|
(17)
|
Incorporated
by reference from the Registrant’s Registration Statement on Form S-1
filed on May 7, 2008.
|
|
(18)
|
Incorporated
by reference from the Registrant’s Registration Statement on Form S-1/A
filed on June 26, 2008.
|
|
(19)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
July 14, 2008.
|
|
(20)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed on
July 15, 2008.
|
|
Incorporated
by reference from the Registrant’s Registration Statement on Form S-1/A
filed on August 21, 2008.
|
(22)
|
Incorporated
by reference from the Registrant’s Registration Statement on Form S-1/A
filed on October 28, 2008.
|
|
(a)
|
The
undersigned registrant hereby undertakes
to:
|
|
(1)
|
File,
during any period in which offers or sales are being made, a
post-effective amendment to this registration statement
to:
|
|
i.
|
Include
any prospectus required by Section 10(a)(3) of the Securities Act
of 1933,
as amended (the “Securities Act”);
|
|
ii.
|
Reflect
in the prospectus any facts or events which, individually or in the
aggregate, represent a fundamental change in the information in the
registration statement. Notwithstanding the foregoing, any increase
or
decrease in volume of securities offered (if the total dollar value
of
securities offered would not exceed that which was registered) and
any
deviation from the low or high end of the estimated maximum offering
range
may be reflected in the form of prospectus filed with the Securities
and
Commission (the “Commission”) pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than
20
percent change in the maximum aggregate offering price set forth
in the
“Calculation of Registration Fee” table in the effective registration
statement.
|
|
iii.
|
Include
any additional or changed material information on the plan of
distribution.
|
|
(2)
|
For
determining liability under the Securities Act, each such post-effective
amendment as a new registration statement relating to the securities
offered, and the offering of such securities at that time shall be
deemed
to be the initial bona
fide
offering.
|
|
(3)
|
File
a post-effective amendment to remove from registration by means of
a
post-effective amendment any of the securities that remain unsold
at the
end of the offering.
|
|
(4)
|
For
determining liability of the undersigned small business issuer under
the
Securities Act to any purchaser in the initial distribution of the
securities, the undersigned small business issuer undertakes that
in a
primary offering of securities of the undersigned small business
issuer
pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities
are
offered or sold to such purchaser by means of any of the following
communications, the undersigned small business issuer will be a seller
to
the purchaser and will be considered to offer or sell such securities
to
such purchaser:
|
|
i.
|
Any
preliminary prospectus or prospectus of the undersigned small business
issuer relating to the offering required to be filed pursuant to
Rule
424;
|
|
ii.
|
Any
free writing prospectus relating to the offering prepared by or on
behalf
of the undersigned small business issuer or used or referred to by
the
undersigned small business issuer;
|
|
iii.
|
The
portion of any other free writing prospectus relating to the offering
containing material information about the undersigned small business
issuer or its securities provided by or on behalf of the undersigned
small
business issuer; and
|
|
iv.
|
Any
other communication that is an offer in the offering made by the
undersigned small business issuer to the
purchaser.
|
|
(b)
|
Provide
to the underwriters at the closing specified in the underwriting
agreements, certificates in such denominations and registered in
such
names as required by the underwriters to permit prompt delivery to
each
purchaser.
|
|
(c)
|
Insofar
as indemnification for liabilities arising under the Securities Act
may be
permitted to directors, officers and controlling persons of the small
business issuer pursuant to the foregoing provisions, or otherwise,
the
small business issuer has been advised that in the opinion of the
Commission such indemnification is against public policy as expressed
in
the Securities Act and is, therefore, unenforceable. In the event
that a
claim for indemnification against such liabilities (other than the
payment
by the small business issuer of expenses incurred or paid by a director,
officer or controlling person of the small business issuer in the
successful defense of any action, suit or proceeding) is asserted
by such
director, officer or controlling person in connection with the securities
being registered, the small business issuer will, unless in the opinion
of
its counsel the matter has been settled by controlling precedent,
submit
to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of
such
issue.
|
|
|
|
|
(d)
|
|
|
|
(1)
|
For
determining any liability under the Securities Act, treat the information
omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus
filed by the small business issuer under Rule 424(b)(1), or (4),
or 497(h)
under the Securities Act as part of this registration statement as
of the
time the Commission declared it effective.
|
|
|
|
|
|
|
(2)
|
For
determining any liability under the Securities Act, treat each
post-effective amendment that contains a form of prospectus as a
new
registration statement for the securities offered in the registration
statement, and that offering of the securities at that time as the
initial
bona
fide
offering of those securities.
|
|
SKYSTAR
BIO-PHARMACEUTICAL COMPANY
(Registrant)
|
|
|
|
|
Date: November
26, 2008
|
By:
|
/s/
Weibing Lu
|
|
Weibing
Lu
Chief
Executive Officer
|
Name
|
|
Title
|
|
Date
|
|
|
|
|
|
*
|
|
Chief
Executive Officer and Director
|
|
|
Weibing
Lu
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
*
|
|
Chief
Financial Officer
|
|
|
Bennet
P. Tchaikovsky
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
*
|
|
Secretary
and Director
|
|
|
Wei
Wen
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
|
R.
Scott Cramer
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
|
Qiang
Fan
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
|
Chengtun
Qu
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
|
Winston
Yen
|
|
|
|
|
|
|
|
|
|
*
|
|
Director
|
|
|
Shouguo
Zhao
|
|
|
|
/s/
Bennet P. Tchaikovsky
|
Attorney-in-fact
*
|
November
26, 2008
|
||
Bennet
P. Tchaikovsky
|